血管内皮生长因子受体2(VEGFR2)检测试剂盒适用生物     Homo sapiens (Human，人)    血管内皮生长因子受体2(VEGFR2)检测试剂盒  检测范围     0.625-40ng/mL     灵敏度     0.252ng/mL    样本类型     Serum, plasma, tissue homogenates and other biological fluids.    实验时长     4.5h     实验方法     双抗夹心法    血管内皮生长因子受体2(VEGFR2)检测试剂盒    规格     96T    ELISA Kit for Vascular Endothelial Growth Factor Receptor 2 (VEGFR2)FOR IN VITRO AND RESEARCH USE ONLY, NOT FOR USE IN CLINICAL DIAGNOSTIC PROCEDURES!Organism species     Homo sapiens (Human)    血管内皮生长因子受体2(VEGFR2)检测试剂盒 Sample type     Serum, plasma, tissue homogenates and other biological fluids.    Format     96-well strip plate    Assay length     4.5 hours    Detection range     0.625-40ng/mL The standard curve concentrations used for the ELISA’s were 40ng/mL, 20ng/mL, 10ng/mL, 5ng/mL, 2.5ng/mL, 1.25ng/mL, 0.625ng/mL    Sensitivity     The minimum detectable dose of this kit is typically less than 0.252ng/mL.    SpecificityThis assay has high sensitivity and excellent specificity for detection of Vascular Endothelial Growth Factor Receptor 2 (VEGFR2). No significant cross-reactivity or interference between Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) and analogues was observed.血管内皮生长因子受体2(VEGFR2)检测试剂盒RecoveryMatrices listed below were spiked with certain level of recombinant Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) and the recovery rates were calculated by comparing the measured value to the expected amount of Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) in samples. Matrix     Recovery range (%)     Average(%)    serum(n=5)     95-103     99    EDTA plasma(n=5)     96-104     101    heparin plasma(n=5)     93-105     101    PrecisionIntra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) were tested 20 times on one plate, respectively. Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) were tested on 3 different plates, 8 replicates in each plate. CV(%) = SD/meanX100 Intra-Assay: CVInter-Assay: CVLinearityThe linearity of the kit was assayed by testing samples spiked with appropriate concentration of Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected. Sample     1:2     1:4     1:8     1:16    serum(n=5)     90-104%     80-97%     79-101%     78-96%    EDTA plasma(n=5)     83-99%     90-105%     86-99%     96-104%    heparin plasma(n=5)     78-90%     89-97%     94-103%     93-101%    血管内皮生长因子受体2(VEGFR2)检测试剂盒StabilityThe stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition. To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.Reagents and materials providedReagents     Quantity     Reagents     Quantity    Pre-coated, ready to use 96-well strip plate     1     Plate sealer for 96 wells     4    Standard     2     Standard Diluent     1×20mL    Detection Reagent A     1×120μL     Assay Diluent A     1×12mL    Detection Reagent B     1×120μL     Assay Diluent B     1×12mL    TMB Substrate     1×9mL     Stop Solution     1×6mL    Wash Buffer (30 × concentrate)     1×20mL     Instruction manual     1    Assay procedure summary1. Prepare all reagents, samples and standards;2. Add 100μL standard or sample to each well. Incubate 2 hours at 37oC;3. Aspirate and add 100μL prepared Detection Reagent A. Incubate 1 hour at 37oC;4. Aspirate and wash 3 times;5. Add 100μL prepared Detection Reagent B. Incubate 30 minutes at 37oC;6. Aspirate and wash 5 times;7. Add 90μL Substrate Solution. Incubate 15-25 minutes at 37oC;8. Add 50μL Stop Solution. Read at 450nm immediately. 血管内皮生长因子受体2(VEGFR2)检测试剂盒Test principleThe test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Vascular Endothelial Growth Factor Receptor 2 (VEGFR2). Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated antibody specific to Vascular Endothelial Growth Factor Receptor 2 (VEGFR2). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Vascular Endothelial Growth Factor Receptor 2 (VEGFR2), biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) in the samples is then determined by comparing the O.D. of the samples to the standard curve. 

血管内皮钙黏蛋白(CDH5)检测试剂盒适用生物     Homo sapiens (Human，人)    血管内皮钙黏蛋白(CDH5)检测试剂盒   检测范围     1.56-100ng/mL     灵敏度     0.69ng/mL    样本类型     Serum, plasma, tissue homogenates and other biological fluids.    实验时长     4.5h     实验方法     双抗夹心法     血管内皮钙黏蛋白(CDH5)检测试剂盒    规格     96T    ELISA Kit for Cadherin 5 (CDH5)FOR IN VITRO AND RESEARCH USE ONLY, NOT FOR USE IN CLINICAL DIAGNOSTIC PROCEDURES!Organism species     Homo sapiens (Human)    血管内皮钙黏蛋白(CDH5)检测试剂盒 Sample type     Serum, plasma, tissue homogenates and other biological fluids.    Format     96-well strip plate    Assay length     4.5 hours    Detection range     1.56-100ng/mL The standard curve concentrations used for the ELISA’s were 100ng/mL, 50ng/mL, 25ng/mL, 12.5ng/mL, 6.25ng/mL, 3.13ng/mL, 1.56ng/mL    Sensitivity     The minimum detectable dose of this kit is typically less than 0.69ng/mL.    SpecificityThis assay has high sensitivity and excellent specificity for detection of Cadherin 5 (CDH5). No significant cross-reactivity or interference between Cadherin 5 (CDH5) and analogues was observed.血管内皮钙黏蛋白(CDH5)检测试剂盒RecoveryMatrices listed below were spiked with certain level of recombinant Cadherin 5 (CDH5) and the recovery rates were calculated by comparing the measured value to the expected amount of Cadherin 5 (CDH5) in samples. Matrix     Recovery range (%)     Average(%)    serum(n=5)     80-90     84    EDTA plasma(n=5)     81-103     87    heparin plasma(n=5)     86-102     95    PrecisionIntra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Cadherin 5 (CDH5) were tested 20 times on one plate, respectively. Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Cadherin 5 (CDH5) were tested on 3 different plates, 8 replicates in each plate. CV(%) = SD/meanX100 Intra-Assay: CVInter-Assay: CVLinearityThe linearity of the kit was assayed by testing samples spiked with appropriate concentration of Cadherin 5 (CDH5) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected. Sample     1:2     1:4     1:8     1:16    serum(n=5)     84-98%     97-105%     92-101%     95-103%    EDTA plasma(n=5)     99-105%     85-99%     83-97%     81-103%    heparin plasma(n=5)     95-103%     91-101%     89-101%     78-104%    StabilityThe stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition. To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.Reagents and materials providedReagents     Quantity     Reagents     Quantity    Pre-coated, ready to use 96-well strip plate     1     Plate sealer for 96 wells     4    Standard     2     Standard Diluent     1×20mL    Detection Reagent A     1×120μL     Assay Diluent A     1×12mL    Detection Reagent B     1×120μL     Assay Diluent B     1×12mL    TMB Substrate     1×9mL     Stop Solution     1×6mL    Wash Buffer (30 × concentrate)     1×20mL     Instruction manual     1    血管内皮钙黏蛋白(CDH5)检测试剂盒Assay procedure summary1. Prepare all reagents, samples and standards;2. Add 100μL standard or sample to each well. Incubate 2 hours at 37oC;3. Aspirate and add 100μL prepared Detection Reagent A. Incubate 1 hour at 37oC;4. Aspirate and wash 3 times;5. Add 100μL prepared Detection Reagent B. Incubate 30 minutes at 37oC;6. Aspirate and wash 5 times;7. Add 90μL Substrate Solution. Incubate 15-25 minutes at 37oC;8. Add 50μL Stop Solution. Read at 450nm immediately. 血管内皮钙黏蛋白(CDH5)检测试剂盒Test principleThe test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Cadherin 5 (CDH5). Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated antibody specific to Cadherin 5 (CDH5). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Cadherin 5 (CDH5), biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Cadherin 5 (CDH5) in the samples is then determined by comparing the O.D. of the samples to the standard curve.

今天，由生物谷主办的2015肿瘤干细胞转化医学论坛在上海好望角大酒店隆重开幕。本次会议邀请来自知名高校，研究所及三甲医院的多位专家、教授作为演讲嘉宾。作为该领域的前言领头人，他们将围绕肿瘤干细胞研究进展与前沿技术、肿瘤干细胞的转化医学及应用、肿瘤干细胞研究面临的挑战与任务等热点议题展开精彩演讲和讨论。肿瘤干细胞(tumor stem cells，TSCs）被认为是恶性肿瘤难以治疗的关键因素之一。肿瘤干细胞也被称为肿瘤起始细胞（tumor initial cells）。肿瘤干细胞一方面可以自我复制保持"干性"，另一方面也可以分化成肿瘤细胞而促进肿瘤的生长。肿瘤干细胞理论，为人们重新认识肿瘤的起源和本质，肿瘤的临床诊断、治疗，以及新药研发提供了新的方向和视角。目前，在血液肿瘤和大部分实体瘤中均发现存在不同表型的肿瘤干细胞。但是，各种TSCs的来源、分离与鉴定、TSCs表型特征、TSCs生物学功能和特异性靶点，都还存在不同程度的争议；另外，肿瘤微环境与肿瘤干细胞之间的关系、肿瘤干细胞与免疫的关系也是争议的焦点。同时，针对肿瘤干细胞的靶向机制，也提出了多种新颖的治疗思路和策略。有理由相信，肿瘤干细胞可能是肿瘤领域未来10年最热的方向之一。此次研讨会为期两天，主要从肿瘤干细胞的基础研究，技术发展和转化医学三方面深入剖析，针对当前研究热点及问题开展交流，与会者将分享该领域最新的研究成果以及他们对肿瘤干细胞转化医学行业的认识与前景预测，为该领域的科学家搭建一个相互沟通交流的平台。本次会议的精彩演讲提炼将在生物谷app会议专区进行推出展示，有兴趣的谷友可以前往各手机应用商城下载生物谷app进行及时关注跟进。

--近日，来自美国的科学家在国际学术期刊the journal of clinical cancer research在线发表了一篇关于发现黑色素瘤潜在药物靶点的文章。 在该项研究中，研究人员在黑色素瘤临床样本中发现了高水皮表达的一种特定酶类，他们认为这种酶是促进黑色素瘤生长的重要因素。这种叫做ITK（interleukin-2 inducible T-cell kinase）的酶在之前研究中从未发现其在实体瘤的生长中有任何作用，在正常情况下，ITK主要在一类免疫细胞亚群中表达。 研究人员指出，ITK在黑色素瘤细胞中高表达，降低ITK活性能够抑制黑色素瘤细胞生长，因此，ITK可能是治疗黑色素瘤的一个潜在药物靶点。但到目前为止，只有一种抑制ITK的药物得到批准应用在血液癌症治疗中，因此开发靶向ITK的治疗药物对于治疗黑色素瘤具有重要意义。 在该研究中，研究人员对正常皮肤组织，非癌性皮肤痣以及黑色素瘤样本进行了分析，结果发现ITK在原位黑色素瘤和转移性黑色素瘤中表达水平更高，并且在转移性黑色素瘤样本中，91%的肿瘤样本其ITK表达水平高于非癌性皮肤痣。当在黑色素瘤细胞中抑制ITK表达，细胞增殖发生减缓同时迁移性减弱，而通过抑制剂抑制ITK酶活性同样能够减弱细胞的增殖和迁移能力。 之前研究表明ITK主要表达在特定免疫细胞亚群，而这项研究发现ITK在黑色素瘤细胞中具有高表达，同时对于促进黑色素瘤细胞生长具有重要作用，因此开发靶向ITK的抑制剂药物或对抑制黑色素瘤生长进而达到治疗效果具有重要意义。

透明质酸结合蛋白1(HABP1)检测试剂盒适用生物     Homo sapiens (Human，人)    透明质酸结合蛋白1(HABP1)检测试剂盒   检测范围     0.156-10ng/mL     灵敏度     0.072ng/mL    样本类型     Serum, plasma and other biological fluids.    实验时长     4.5h     实验方法     双抗夹心法     透明质酸结合蛋白1(HABP1)检测试剂盒规格     96T    ELISA Kit for Hyaluronan Binding Protein 1 (HABP1)FOR IN VITRO AND RESEARCH USE ONLY, NOT FOR USE IN CLINICAL DIAGNOSTIC PROCEDURES!Organism species     Homo sapiens (Human)    Product No.     hzEA651Hu    Sample type     Serum, plasma and other biological fluids.    Format     96-well strip plate    Assay length     4.5 hours    Detection range     0.156-10ng/mL The standard curve concentrations used for the ELISA’s were 10ng/mL, 5ng/mL, 2.5ng/mL, 1.25ng/mL, 0.625ng/mL, 0.313ng/mL, 0.156ng/mL    Sensitivity     The minimum detectable dose of this kit is typically less than 0.072ng/mL.    SpecificityThis assay has high sensitivity and excellent specificity for detection of Hyaluronan Binding Protein 1 (HABP1). No significant cross-reactivity or interference between Hyaluronan Binding Protein 1 (HABP1) and analogues was observed.透明质酸结合蛋白1(HABP1)检测试剂盒RecoveryMatrices listed below were spiked with certain level of recombinant Hyaluronan Binding Protein 1 (HABP1) and the recovery rates were calculated by comparing the measured value to the expected amount of Hyaluronan Binding Protein 1 (HABP1) in samples. Matrix     Recovery range (%)     Average(%)    serum(n=5)     82-93     89    EDTA plasma(n=5)     81-91     86    heparin plasma(n=5)     99-105     102    PrecisionIntra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Hyaluronan Binding Protein 1 (HABP1) were tested 20 times on one plate, respectively. Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Hyaluronan Binding Protein 1 (HABP1) were tested on 3 different plates, 8 replicates in each plate. CV(%) = SD/meanX100 Intra-Assay: CVInter-Assay: CVLinearityThe linearity of the kit was assayed by testing samples spiked with appropriate concentration of Hyaluronan Binding Protein 1 (HABP1) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected. Sample     1:2     1:4     1:8     1:16    serum(n=5)     92-99%     78-101%     96-105%     90-101%    EDTA plasma(n=5)     87-96%     90-104%     83-92%     79-102%    heparin plasma(n=5)     97-105%     95-103%     89-104%     93-102%    透明质酸结合蛋白1(HABP1)检测试剂盒StabilityThe stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition. To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.Reagents and materials providedReagents     Quantity     Reagents     Quantity    Pre-coated, ready to use 96-well strip plate     1     Plate sealer for 96 wells     4    Standard     2     Standard Diluent     1×20mL    Detection Reagent A     1×120μL     Assay Diluent A     1×12mL    Detection Reagent B     1×120μL     Assay Diluent B     1×12mL    TMB Substrate     1×9mL     Stop Solution     1×6mL    Wash Buffer (30 × concentrate)     1×20mL     Instruction manual     1    Assay procedure summary1. Prepare all reagents, samples and standards;2. Add 100μL standard or sample to each well. Incubate 2 hours at 37oC;3. Aspirate and add 100μL prepared Detection Reagent A. Incubate 1 hour at 37oC;4. Aspirate and wash 3 times;5. Add 100μL prepared Detection Reagent B. Incubate 30 minutes at 37oC;6. Aspirate and wash 5 times;7. Add 90μL Substrate Solution. Incubate 15-25 minutes at 37oC;8. Add 50μL Stop Solution. Read at 450nm immediately. 透明质酸结合蛋白1(HABP1)检测试剂盒Test principleThe test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Hyaluronan Binding Protein 1 (HABP1). Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated antibody specific to Hyaluronan Binding Protein 1 (HABP1). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Hyaluronan Binding Protein 1 (HABP1), biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Hyaluronan Binding Protein 1 (HABP1) in the samples is then determined by comparing the O.D. of the samples to the standard curve.

血小板因子4(PF4)检测试剂盒适用生物     Oryctolagus cuniculus (Rabbit，兔)    血小板因子4(PF4)检测试剂盒    检测范围     7.81-500ng/mL     灵敏度     3.2ng/mL    样本类型     Serum, platelet-poor plasma.    实验时长     4.5h     实验方法     双抗夹心法     血小板因子4(PF4)检测试剂盒规格     96T    ELISA Kit for Platelet Factor 4 (PF4)FOR IN VITRO AND RESEARCH USE ONLY, NOT FOR USE IN CLINICAL DIAGNOSTIC PROCEDURES!Organism species     Oryctolagus cuniculus (Rabbit)    Product No.     hzEA172Rb    Sample type     Serum, platelet-poor plasma.    Format     96-well strip plate    Assay length     4.5 hours    Detection range     7.81-500ng/mL The standard curve concentrations used for the ELISA’s were 500ng/mL, 250ng/mL, 125ng/mL, 62.5ng/mL, 31.25ng/mL, 15.63ng/mL, 7.81ng/mL    Sensitivity     The minimum detectable dose of this kit is typically less than 3.2ng/mL.    SpecificityThis assay has high sensitivity and excellent specificity for detection of Platelet Factor 4 (PF4). No significant cross-reactivity or interference between Platelet Factor 4 (PF4) and analogues was observed.RecoveryMatrices listed below were spiked with certain level of recombinant Platelet Factor 4 (PF4) and the recovery rates were calculated by comparing the measured value to the expected amount of Platelet Factor 4 (PF4) in samples. Matrix     Recovery range (%)     Average(%)    serum(n=5)     82-101     86    EDTA plasma(n=5)     78-91     85    heparin plasma(n=5)     79-96     92    血小板因子4(PF4)检测试剂盒PrecisionIntra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Platelet Factor 4 (PF4) were tested 20 times on one plate, respectively. Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Platelet Factor 4 (PF4) were tested on 3 different plates, 8 replicates in each plate. CV(%) = SD/meanX100 Intra-Assay: CVInter-Assay: CVLinearityThe linearity of the kit was assayed by testing samples spiked with appropriate concentration of Platelet Factor 4 (PF4) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected. Sample     1:2     1:4     1:8     1:16    serum(n=5)     92-102%     93-105%     82-94%     86-98%    EDTA plasma(n=5)     91-104%     80-90%     84-105%     94-105%    heparin plasma(n=5)     78-101%     82-92%     95-104%     98-105%    StabilityThe stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition. To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.血小板因子4(PF4)检测试剂盒Reagents and materials providedReagents     Quantity     Reagents     Quantity    Pre-coated, ready to use 96-well strip plate     1     Plate sealer for 96 wells     4    Standard     2     Standard Diluent     1×20mL    Detection Reagent A     1×120μL     Assay Diluent A     1×12mL    Detection Reagent B     1×120μL     Assay Diluent B     1×12mL    TMB Substrate     1×9mL     Stop Solution     1×6mL    Wash Buffer (30 × concentrate)     1×20mL     Instruction manual     1    Assay procedure summary1. Prepare all reagents, samples and standards;2. Add 100μL standard or sample to each well. Incubate 2 hours at 37oC;3. Aspirate and add 100μL prepared Detection Reagent A. Incubate 1 hour at 37oC;4. Aspirate and wash 3 times;5. Add 100μL prepared Detection Reagent B. Incubate 30 minutes at 37oC;6. Aspirate and wash 5 times;7. Add 90μL Substrate Solution. Incubate 15-25 minutes at 37oC;8. Add 50μL Stop Solution. Read at 450nm immediately. 血小板因子4(PF4)检测试剂盒Test principleThe test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Platelet Factor 4 (PF4). Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated antibody specific to Platelet Factor 4 (PF4). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Platelet Factor 4 (PF4), biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Platelet Factor 4 (PF4) in the samples is then determined by comparing the O.D. of the samples to the standard curve.

亲环素A(CYPA)检测试剂盒适用生物     Mus musculus (Mouse，小鼠)    亲环素A(CYPA)检测试剂盒   检测范围     7.81-500pg/mL     灵敏度     3.3pg/mL    样本类型     Serum, plasma, tissue homogenates and other biological fluids.    实验时长     4.5h     实验方法     双抗夹心法     亲环素A(CYPA)检测试剂盒规格     96T    ELISA Kit for Cyclophilin A (CYPA)FOR IN VITRO AND RESEARCH USE ONLY, NOT FOR USE IN CLINICAL DIAGNOSTIC PROCEDURES!Organism species     Mus musculus (Mouse)    Product No.     hzEA979Mu    Sample type     Serum, plasma, tissue homogenates and other biological fluids.    Format     96-well strip plate    Assay length     4.5 hours    Detection range     7.81-500pg/mL The standard curve concentrations used for the ELISA’s were 500pg/mL, 250pg/mL, 125pg/mL, 62.5pg/mL, 31.25pg/mL, 15.63pg/mL, 7.81pg/mL    Sensitivity     The minimum detectable dose of this kit is typically less than 3.3pg/mL.    亲环素A(CYPA)检测试剂盒SpecificityThis assay has high sensitivity and excellent specificity for detection of Cyclophilin A (CYPA). No significant cross-reactivity or interference between Cyclophilin A (CYPA) and analogues was observed.RecoveryMatrices listed below were spiked with certain level of recombinant Cyclophilin A (CYPA) and the recovery rates were calculated by comparing the measured value to the expected amount of Cyclophilin A (CYPA) in samples. Matrix     Recovery range (%)     Average(%)    serum(n=5)     84-101     95    EDTA plasma(n=5)     88-104     101    heparin plasma(n=5)     97-105     101    PrecisionIntra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Cyclophilin A (CYPA) were tested 20 times on one plate, respectively. Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Cyclophilin A (CYPA) were tested on 3 different plates, 8 replicates in each plate. CV(%) = SD/meanX100 Intra-Assay: CVInter-Assay: CVLinearityThe linearity of the kit was assayed by testing samples spiked with appropriate concentration of Cyclophilin A (CYPA) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected. Sample     1:2     1:4     1:8     1:16    serum(n=5)     93-101%     86-101%     94-103%     85-99%    EDTA plasma(n=5)     97-105%     94-102%     97-104%     95-102%    heparin plasma(n=5)     90-104%     91-99%     85-99%     84-98%    亲环素A(CYPA)检测试剂盒StabilityThe stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition. To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.Reagents and materials providedReagents     Quantity     Reagents     Quantity    Pre-coated, ready to use 96-well strip plate     1     Plate sealer for 96 wells     4    Standard     2     Standard Diluent     1×20mL    Detection Reagent A     1×120μL     Assay Diluent A     1×12mL    Detection Reagent B     1×120μL     Assay Diluent B     1×12mL    TMB Substrate     1×9mL     Stop Solution     1×6mL    Wash Buffer (30 × concentrate)     1×20mL     Instruction manual     1    Assay procedure summary1. Prepare all reagents, samples and standards;2. Add 100μL standard or sample to each well. Incubate 2 hours at 37oC;3. Aspirate and add 100μL prepared Detection Reagent A. Incubate 1 hour at 37oC;4. Aspirate and wash 3 times;5. Add 100μL prepared Detection Reagent B. Incubate 30 minutes at 37oC;6. Aspirate and wash 5 times;7. Add 90μL Substrate Solution. Incubate 15-25 minutes at 37oC;8. Add 50μL Stop Solution. Read at 450nm immediately. 亲环素A(CYPA)检测试剂盒Test principleThe test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Cyclophilin A (CYPA). Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated antibody specific to Cyclophilin A (CYPA). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Cyclophilin A (CYPA), biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Cyclophilin A (CYPA) in the samples is then determined by comparing the O.D. of the samples to the standard curve.

簇集蛋白(CLU)检测试剂盒适用生物     Homo sapiens (Human，人)    簇集蛋白(CLU)检测试剂盒   检测范围     62.5-4000ng/mL     灵敏度     29.6ng/mL    样本类型     Serum, plasma, urine, saliva, tissue homogenates, cerebrospinal fluid, cell culture supernates and other biological fluids.    实验时长     4.5h     实验方法     双抗夹心法     簇集蛋白(CLU)检测试剂盒规格     96T    ELISA Kit for Clusterin (CLU)FOR IN VITRO AND RESEARCH USE ONLY, NOT FOR USE IN CLINICAL DIAGNOSTIC PROCEDURES!Organism species     Homo sapiens (Human)    Product No.     SEB180Hu    Sample type     Serum, plasma, urine, saliva, tissue homogenates, cerebrospinal fluid, cell culture supernates and other biological fluids.    Format     96-well strip plate    Assay length     4.5 hours    Detection range     62.5-4000ng/mL The standard curve concentrations used for the ELISA’s were 4000ng/mL, 2000ng/mL, 1000ng/mL, 500ng/mL, 250ng/mL, 125ng/mL, 62.5ng/mL    Sensitivity     The minimum detectable dose of this kit is typically less than 29.6ng/mL.    SpecificityThis assay has high sensitivity and excellent specificity for detection of Clusterin (CLU). No significant cross-reactivity or interference between Clusterin (CLU) and analogues was observed.RecoveryMatrices listed below were spiked with certain level of recombinant Clusterin (CLU) and the recovery rates were calculated by comparing the measured value to the expected amount of Clusterin (CLU) in samples. Matrix     Recovery range (%)     Average(%)    serum(n=5)     97-105     101    EDTA plasma(n=5)     78-105     93    heparin plasma(n=5)     78-95     86    簇集蛋白(CLU)检测试剂盒PrecisionIntra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Clusterin (CLU) were tested 20 times on one plate, respectively. Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Clusterin (CLU) were tested on 3 different plates, 8 replicates in each plate. CV(%) = SD/meanX100 Intra-Assay: CVInter-Assay: CVLinearityThe linearity of the kit was assayed by testing samples spiked with appropriate concentration of Clusterin (CLU) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected. Sample     1:2     1:4     1:8     1:16    serum(n=5)     87-96%     81-101%     92-99%     91-102%    EDTA plasma(n=5)     94-105%     87-95%     85-93%     80-88%    heparin plasma(n=5)     92-101%     89-103%     92-101%     86-103%    StabilityThe stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition. To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.Reagents and materials providedReagents     Quantity     Reagents     Quantity    Pre-coated, ready to use 96-well strip plate     1     Plate sealer for 96 wells     4    Standard     2     Standard Diluent     1×20mL    Detection Reagent A     1×120μL     Assay Diluent A     1×12mL    Detection Reagent B     1×120μL     Assay Diluent B     1×12mL    TMB Substrate     1×9mL     Stop Solution     1×6mL    Wash Buffer (30 × concentrate)     1×20mL     Instruction manual     1    簇集蛋白(CLU)检测试剂盒Assay procedure summary1. Prepare all reagents, samples and standards;2. Add 100μL standard or sample to each well. Incubate 2 hours at 37oC;3. Aspirate and add 100μL prepared Detection Reagent A. Incubate 1 hour at 37oC;4. Aspirate and wash 3 times;5. Add 100μL prepared Detection Reagent B. Incubate 30 minutes at 37oC;6. Aspirate and wash 5 times;7. Add 90μL Substrate Solution. Incubate 15-25 minutes at 37oC;8. Add 50μL Stop Solution. Read at 450nm immediately. 簇集蛋白(CLU)检测试剂盒Test principleThe test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Clusterin (CLU). Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated antibody specific to Clusterin (CLU). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Clusterin (CLU), biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Clusterin (CLU) in the samples is then determined by comparing the O.D. of the samples to the standard curve.

低分子量激肽原(LMWK)检测试剂盒适用生物     Homo sapiens (Human，人)    低分子量激肽原(LMWK)检测试剂盒检测范围     6.25-400ng/mL     灵敏度     2.54ng/mL    样本类型     Plasma.    实验时长     4.5h     实验方法     双抗夹心法    低分子量激肽原(LMWK)检测试剂盒规格     96T    ELISA Kit for Low Molecular Weight Kininogen (LMWK)FOR IN VITRO AND RESEARCH USE ONLY, NOT FOR USE IN CLINICAL DIAGNOSTIC PROCEDURES!Organism species     Homo sapiens (Human)    Product No.     SEB177Hu    Sample type     Plasma.    Format     96-well strip plate    Assay length     4.5 hours    Detection range     6.25-400ng/mL The standard curve concentrations used for the ELISA’s were 400ng/mL, 200ng/mL, 100ng/mL, 50ng/mL, 25ng/mL, 12.5ng/mL, 6.25ng/mL    Sensitivity     The minimum detectable dose of this kit is typically less than 2.54ng/mL.    低分子量激肽原(LMWK)检测试剂盒SpecificityThis assay has high sensitivity and excellent specificity for detection of Low Molecular Weight Kininogen (LMWK). No significant cross-reactivity or interference between Low Molecular Weight Kininogen (LMWK) and analogues was observed.RecoveryMatrices listed below were spiked with certain level of recombinant Low Molecular Weight Kininogen (LMWK) and the recovery rates were calculated by comparing the measured value to the expected amount of Low Molecular Weight Kininogen (LMWK) in samples. Matrix     Recovery range (%)     Average(%)    sodium citrate plasma(n=5)     87-97     91    PrecisionIntra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Low Molecular Weight Kininogen (LMWK) were tested 20 times on one plate, respectively. Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Low Molecular Weight Kininogen (LMWK) were tested on 3 different plates, 8 replicates in each plate. CV(%) = SD/meanX100 Intra-Assay: CVInter-Assay: CV低分子量激肽原(LMWK)检测试剂盒LinearityThe linearity of the kit was assayed by testing samples spiked with appropriate concentration of Low Molecular Weight Kininogen (LMWK) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected. Sample     1:2     1:4     1:8     1:16    sodium citrate plasma(n=5)     90-101%     95-105%     84-98%     95-103%    StabilityThe stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition. To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.Reagents and materials providedReagents     Quantity     Reagents     Quantity    Pre-coated, ready to use 96-well strip plate     1     Plate sealer for 96 wells     4    Standard     2     Standard Diluent     1×20mL    Detection Reagent A     1×120μL     Assay Diluent A     1×12mL    Detection Reagent B     1×120μL     Assay Diluent B     1×12mL    TMB Substrate     1×9mL     Stop Solution     1×6mL    Wash Buffer (30 × concentrate)     1×20mL     Instruction manual     1    Assay procedure summary1. Prepare all reagents, samples and standards;2. Add 100μL standard or sample to each well. Incubate 2 hours at 37oC;3. Aspirate and add 100μL prepared Detection Reagent A. Incubate 1 hour at 37oC;4. Aspirate and wash 3 times;5. Add 100μL prepared Detection Reagent B. Incubate 30 minutes at 37oC;6. Aspirate and wash 5 times;7. Add 90μL Substrate Solution. Incubate 15-25 minutes at 37oC;8. Add 50μL Stop Solution. Read at 450nm immediately. 低分子量激肽原(LMWK)检测试剂盒Test principleThe test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Low Molecular Weight Kininogen (LMWK). Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated antibody specific to Low Molecular Weight Kininogen (LMWK). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Low Molecular Weight Kininogen (LMWK), biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Low Molecular Weight Kininogen (LMWK) in the samples is then determined by comparing the O.D. of the samples to the standard curve.

--近日，来自美国加州大学圣地亚哥分校的研究人员在国际学术期刊the Journal of Steroid Biochemistry and Molecular Biology在线发表了一项最新研究进展，他们发现胰腺癌发生率在光照较少的国家发生率最高，这种关联性可能与维生素D的合成有关。 在该项研究中，研究人员对来自107个国家的人群数据进行了分析，并将国家间差异以及饮酒、肥胖和吸烟情况考虑在内。结果发现生活在高纬度或云层较厚区域的人，一年中大部分时间都不能够合成维生素D，这可能是导致胰腺癌发生风险高于正常水平的重要原因。同时，生活在赤道附近阳光充足区域的人们其胰腺癌发生率仅是远离赤道区域的人们的六分之一，这表明维生素D的缺陷可能是促进胰腺癌发生风险的重要因素。 自然界中含有维生素D的天然食物种类较少，除了从食物中摄取维生素D，人体还需要通过皮肤在阳光下照射下进行维生素D的合成，但隔着窗户在室内进行阳光照射并不能产生维生素D。 之前一些研究已经发现血清中的一种维生素D代谢产物与乳腺癌和结肠癌发生有关，而这项研究首次提出维生素D缺陷与胰腺癌发生有关。 胰腺癌是世界上排名第十二位的常见癌症，每年诊断出大约338,000名病人患有胰腺癌，并且胰腺癌的致死率非常高，该项研究发现胰腺癌的发生可能与光照产生的维生素D水平有关，对于阐述胰腺癌发生的地域差异具有一定意义。

近日一项研究表明，肺癌病人在诊断前或诊断后服用他汀类药物可降低肺癌造成的死亡风险。 一名来自北爱尔兰的研究人员指出：这项研究为肺癌病人服用他汀类药物可降低肺癌造成的死亡风险提供了一些证据。但他同时也说道，两者之间但关系并不是特别显著，他汀类药物服用者可能在其他一些方面与未服用他汀类药物的病人存在不同，导致他们因肺癌造成的死亡率降低，但这一发现仍值得进一步的观察研究。 在该项研究中，研究人员利用了接近1,4000份在1998年到2009年间诊断为肺癌的病人资料，并将这些病人的处方纪录与截至2012年的病人死亡数据进行了分析。结果发现在诊断后存活超过6个月的病人中，服用他汀类药物的病人因肺癌导致的死亡率有11%的下降，但这一数据不存在统计学意义。而服用了超过12个月他汀类药物的肺癌病人，因肺癌导致的死亡率下降了19%，并且这一结果存在统计学意义。该研究所有病人中，在诊断前就服用他汀类药物的病人其因肺癌导致的死亡率显著下降了12%。 最后，研究人员指出，这一结果在非小细胞肺癌病人和小细胞肺癌病人之间并没有什么不同，并且他们希望通过扩大肺癌病人数据量来进一步验证这一发现。（

Dickkopf相关蛋白2(DKK2)检测试剂盒适用生物     Homo sapiens (Human，人)    Dickkopf相关蛋白2(DKK2)检测试剂盒   检测范围     78.13-5000pg/mL     灵敏度     35pg/mL    样本类型     Serum, plasma, tissue homogenates and other biological fluids.    实验时长     4.5h     实验方法     双抗夹心法     Dickkopf相关蛋白2(DKK2)检测试剂盒规格     96T    Dickkopf相关蛋白2(DKK2)检测试剂盒   ELISA Kit for Dickkopf Related Protein 2 (DKK2)FOR IN VITRO AND RESEARCH USE ONLY, NOT FOR USE IN CLINICAL DIAGNOSTIC PROCEDURES!Organism species     Homo sapiens (Human)    Product No.     SEB033Hu    Sample type     Serum, plasma, tissue homogenates and other biological fluids.    Format     96-well strip plate    Assay length     4.5 hours    Detection range     78.13-5000pg/mL The standard curve concentrations used for the ELISA’s were 5000pg/mL, 2500pg/mL, 1250pg/mL, 625pg/mL, 312.5pg/mL, 156.25pg/mL, 78.13pg/mL    Sensitivity     The minimum detectable dose of this kit is typically less than 35pg/mL.    SpecificityThis assay has high sensitivity and excellent specificity for detection of Dickkopf Related Protein 2 (DKK2). No significant cross-reactivity or interference between Dickkopf Related Protein 2 (DKK2) and analogues was observed.RecoveryMatrices listed below were spiked with certain level of recombinant Dickkopf Related Protein 2 (DKK2) and the recovery rates were calculated by comparing the measured value to the expected amount of Dickkopf Related Protein 2 (DKK2) in samples. Matrix     Recovery range (%)     Average(%)    serum(n=5)     95-105     101    EDTA plasma(n=5)     94-101     98    heparin plasma(n=5)     92-101     95    PrecisionIntra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Dickkopf Related Protein 2 (DKK2) were tested 20 times on one plate, respectively. Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Dickkopf Related Protein 2 (DKK2) were tested on 3 different plates, 8 replicates in each plate. CV(%) = SD/meanX100 Intra-Assay: CVInter-Assay: CVLinearityThe linearity of the kit was assayed by testing samples spiked with appropriate concentration of Dickkopf Related Protein 2 (DKK2) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected. Sample     1:2     1:4     1:8     1:16    serum(n=5)     93-101%     93-105%     79-96%     88-96%    EDTA plasma(n=5)     93-101%     80-94%     91-98%     93-105%    heparin plasma(n=5)     97-105%     86-105%     78-103%     93-101%    StabilityThe stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition. To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.Reagents and materials providedReagents     Quantity     Reagents     Quantity    Pre-coated, ready to use 96-well strip plate     1     Plate sealer for 96 wells     4    Standard     2     Standard Diluent     1×20mL    Detection Reagent A     1×120μL     Assay Diluent A     1×12mL    Detection Reagent B     1×120μL     Assay Diluent B     1×12mL    TMB Substrate     1×9mL     Stop Solution     1×6mL    Wash Buffer (30 × concentrate)     1×20mL     Instruction manual     1    Assay procedure summary1. Prepare all reagents, samples and standards;2. Add 100μL standard or sample to each well. Incubate 2 hours at 37oC;3. Aspirate and add 100μL prepared Detection Reagent A. Incubate 1 hour at 37oC;4. Aspirate and wash 3 times;5. Add 100μL prepared Detection Reagent B. Incubate 30 minutes at 37oC;6. Aspirate and wash 5 times;7. Add 90μL Substrate Solution. Incubate 15-25 minutes at 37oC;8. Add 50μL Stop Solution. Read at 450nm immediately. Test principleThe test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Dickkopf Related Protein 2 (DKK2). Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated antibody specific to Dickkopf Related Protein 2 (DKK2). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Dickkopf Related Protein 2 (DKK2), biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Dickkopf Related Protein 2 (DKK2) in the samples is then determined by comparing the O.D. of the samples to the standard curve.

磷脂酰肌醇蛋白聚糖1(GPC1)检测试剂盒适用生物     Homo sapiens (Human，人)    磷脂酰肌醇蛋白聚糖1(GPC1)检测试剂盒   检测范围     0.781-50ng/mL     灵敏度     0.32ng/mL    样本类型     Serum, plasma, tissue homogenates and other biological fluids.    实验时长     4.5h     实验方法     双抗夹心法     磷脂酰肌醇蛋白聚糖1(GPC1)检测试剂盒规格     96T    磷脂酰肌醇蛋白聚糖1(GPC1)检测试剂盒     ELISA Kit for Glypican 1 (GPC1)FOR IN VITRO AND RESEARCH USE ONLY, NOT FOR USE IN CLINICAL DIAGNOSTIC PROCEDURES!Organism species     Homo sapiens (Human)    Product No.     SEB032Hu    Sample type     Serum, plasma, tissue homogenates and other biological fluids.    Format     96-well strip plate    Assay length     4.5 hours    Detection range     0.781-50ng/mL The standard curve concentrations used for the ELISA’s were 50ng/mL, 25ng/mL, 12.5ng/mL, 6.25ng/mL, 3.125ng/mL, 1.563ng/mL, 0.781ng/mL    Sensitivity     The minimum detectable dose of this kit is typically less than 0.32ng/mL.    SpecificityThis assay has high sensitivity and excellent specificity for detection of Glypican 1 (GPC1). No significant cross-reactivity or interference between Glypican 1 (GPC1) and analogues was observed.RecoveryMatrices listed below were spiked with certain level of recombinant Glypican 1 (GPC1) and the recovery rates were calculated by comparing the measured value to the expected amount of Glypican 1 (GPC1) in samples. Matrix     Recovery range (%)     Average(%)    serum(n=5)     83-103     88    EDTA plasma(n=5)     96-103     99    heparin plasma(n=5)     91-101     97    PrecisionIntra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Glypican 1 (GPC1) were tested 20 times on one plate, respectively. Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Glypican 1 (GPC1) were tested on 3 different plates, 8 replicates in each plate. CV(%) = SD/meanX100 Intra-Assay: CVInter-Assay: CVLinearityThe linearity of the kit was assayed by testing samples spiked with appropriate concentration of Glypican 1 (GPC1) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected. Sample     1:2     1:4     1:8     1:16    serum(n=5)     91-98%     80-92%     97-105%     87-95%    EDTA plasma(n=5)     78-105%     95-105%     78-99%     86-102%    heparin plasma(n=5)     89-96%     98-105%     97-105%     80-94%    StabilityThe stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition. To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.Reagents and materials providedReagents     Quantity     Reagents     Quantity    Pre-coated, ready to use 96-well strip plate     1     Plate sealer for 96 wells     4    Standard     2     Standard Diluent     1×20mL    Detection Reagent A     1×120μL     Assay Diluent A     1×12mL    Detection Reagent B     1×120μL     Assay Diluent B     1×12mL    TMB Substrate     1×9mL     Stop Solution     1×6mL    Wash Buffer (30 × concentrate)     1×20mL     Instruction manual     1    Assay procedure summary1. Prepare all reagents, samples and standards;2. Add 100μL standard or sample to each well. Incubate 2 hours at 37oC;3. Aspirate and add 100μL prepared Detection Reagent A. Incubate 1 hour at 37oC;4. Aspirate and wash 3 times;5. Add 100μL prepared Detection Reagent B. Incubate 30 minutes at 37oC;6. Aspirate and wash 5 times;7. Add 90μL Substrate Solution. Incubate 15-25 minutes at 37oC;8. Add 50μL Stop Solution. Read at 450nm immediately. Test principleThe test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Glypican 1 (GPC1). Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated antibody specific to Glypican 1 (GPC1). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Glypican 1 (GPC1), biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Glypican 1 (GPC1) in the samples is then determined by comparing the O.D. of the samples to the standard curve.

粘蛋白3(MUC3)检测试剂盒适用生物     Homo sapiens (Human，人)    粘蛋白3(MUC3)检测试剂盒    检测范围     62.5-4000pg/mL     灵敏度     23.6pg/mL    样本类型     Serum, plasma, tissue homogenates, cell lysates and other biological fluids.    实验时长     4.5h     实验方法     双抗夹心法     粘蛋白3(MUC3)检测试剂盒规格     96T    粘蛋白3(MUC3)检测试剂盒       ELISA Kit for Mucin 3 (MUC3)FOR IN VITRO AND RESEARCH USE ONLY, NOT FOR USE IN CLINICAL DIAGNOSTIC PROCEDURES!Organism species     Homo sapiens (Human)    Product No.     SEB031Hu    Sample type     Serum, plasma, tissue homogenates, cell lysates and other biological fluids.    Format     96-well strip plate    Assay length     4.5 hours    Detection range     62.5-4000pg/mL The standard curve concentrations used for the ELISA’s were 4000pg/mL, 2000pg/mL, 1000pg/mL, 500pg/mL, 250pg/mL, 125pg/mL, 62.5pg/mL    Sensitivity     The minimum detectable dose of this kit is typically less than 23.6pg/mL.    SpecificityThis assay has high sensitivity and excellent specificity for detection of Mucin 3 (MUC3). No significant cross-reactivity or interference between Mucin 3 (MUC3) and analogues was observed.RecoveryMatrices listed below were spiked with certain level of recombinant Mucin 3 (MUC3) and the recovery rates were calculated by comparing the measured value to the expected amount of Mucin 3 (MUC3) in samples. Matrix     Recovery range (%)     Average(%)    serum(n=5)     97-105     101    EDTA plasma(n=5)     96-104     99    heparin plasma(n=5)     80-104     83    PrecisionIntra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Mucin 3 (MUC3) were tested 20 times on one plate, respectively. Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Mucin 3 (MUC3) were tested on 3 different plates, 8 replicates in each plate. CV(%) = SD/meanX100 Intra-Assay: CVInter-Assay: CVLinearityThe linearity of the kit was assayed by testing samples spiked with appropriate concentration of Mucin 3 (MUC3) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected. Sample     1:2     1:4     1:8     1:16    serum(n=5)     97-104%     99-105%     85-101%     81-103%    EDTA plasma(n=5)     82-89%     82-91%     86-95%     80-89%    heparin plasma(n=5)     95-102%     92-99%     86-94%     94-103%    StabilityThe stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition. To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.Reagents and materials providedReagents     Quantity     Reagents     Quantity    Pre-coated, ready to use 96-well strip plate     1     Plate sealer for 96 wells     4    Standard     2     Standard Diluent     1×20mL    Detection Reagent A     1×120μL     Assay Diluent A     1×12mL    Detection Reagent B     1×120μL     Assay Diluent B     1×12mL    TMB Substrate     1×9mL     Stop Solution     1×6mL    Wash Buffer (30 × concentrate)     1×20mL     Instruction manual     1    Assay procedure summary1. Prepare all reagents, samples and standards;2. Add 100μL standard or sample to each well. Incubate 2 hours at 37oC;3. Aspirate and add 100μL prepared Detection Reagent A. Incubate 1 hour at 37oC;4. Aspirate and wash 3 times;5. Add 100μL prepared Detection Reagent B. Incubate 30 minutes at 37oC;6. Aspirate and wash 5 times;7. Add 90μL Substrate Solution. Incubate 15-25 minutes at 37oC;8. Add 50μL Stop Solution. Read at 450nm immediately. Test principleThe test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Mucin 3 (MUC3). Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated antibody specific to Mucin 3 (MUC3). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Mucin 3 (MUC3), biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Mucin 3 (MUC3) in the samples is then determined by comparing the O.D. of the samples to the standard curve.

表面活性物质关联蛋白A(SPA)检测试剂盒适用生物 Homo sapiens (Human，人) 检测范围 46.88-3000pg/mL 灵敏度 19.47pg/mL 样本类型 Serum, plasma, tissue homogenates, cell lysates, lung lavage fluid, cell culture supernates and other biological fluids. 实验时长 4.5h 实验方法 双抗夹心法  规格 96T 表面活性物质关联蛋白A(SPA)检测试剂盒ELISA Kit for Surfactant Associated Protein A (SPA)FOR IN VITRO AND RESEARCH USE ONLY, NOT FOR USE IN CLINICAL DIAGNOSTIC PROCEDURES!Organism species     Homo sapiens (Human)    Product No.     SEA890Hu    Sample type     Serum, plasma, tissue homogenates, cell lysates, lung lavage fluid, cell culture supernates and other biological fluids.    Format     96-well strip plate    Assay length     4.5 hours    Detection range     46.88-3000pg/mL The standard curve concentrations used for the ELISA’s were 3000pg/mL, 1500pg/mL, 750pg/mL, 375pg/mL, 187.5pg/mL, 93.75pg/mL, 46.88pg/mL    Sensitivity     The minimum detectable dose of this kit is typically less than 19.47pg/mL.    表面活性物质关联蛋白A(SPA)检测试剂盒SpecificityThis assay has high sensitivity and excellent specificity for detection of Surfactant Associated Protein A (SPA). No significant cross-reactivity or interference between Surfactant Associated Protein A (SPA) and analogues was observed.RecoveryMatrices listed below were spiked with certain level of recombinant Surfactant Associated Protein A (SPA) and the recovery rates were calculated by comparing the measured value to the expected amount of Surfactant Associated Protein A (SPA) in samples. Matrix     Recovery range (%)     Average(%)    serum(n=5)     96-104     101    EDTA plasma(n=5)     98-105     101    heparin plasma(n=5)     80-90     84    表面活性物质关联蛋白A(SPA)检测试剂盒PrecisionIntra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Surfactant Associated Protein A (SPA) were tested 20 times on one plate, respectively. Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Surfactant Associated Protein A (SPA) were tested on 3 different plates, 8 replicates in each plate. CV(%) = SD/meanX100 Intra-Assay: CVInter-Assay: CVLinearityThe linearity of the kit was assayed by testing samples spiked with appropriate concentration of Surfactant Associated Protein A (SPA) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected. Sample     1:2     1:4     1:8     1:16    serum(n=5)     78-91%     93-105%     92-101%     78-91%    EDTA plasma(n=5)     96-105%     92-105%     95-105%     80-104%    heparin plasma(n=5)     97-105%     90-97%     96-105%     81-101%    表面活性物质关联蛋白A(SPA)检测试剂盒StabilityThe stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition. To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.Reagents and materials providedReagents     Quantity     Reagents     Quantity    Pre-coated, ready to use 96-well strip plate     1     Plate sealer for 96 wells     4    Standard     2     Standard Diluent     1×20mL    Detection Reagent A     1×120μL     Assay Diluent A     1×12mL    Detection Reagent B     1×120μL     Assay Diluent B     1×12mL    TMB Substrate     1×9mL     Stop Solution     1×6mL    Wash Buffer (30 × concentrate)     1×20mL     Instruction manual     1    Assay procedure summary1. Prepare all reagents, samples and standards;2. Add 100μL standard or sample to each well. Incubate 2 hours at 37oC;3. Aspirate and add 100μL prepared Detection Reagent A. Incubate 1 hour at 37oC;4. Aspirate and wash 3 times;5. Add 100μL prepared Detection Reagent B. Incubate 30 minutes at 37oC;6. Aspirate and wash 5 times;7. Add 90μL Substrate Solution. Incubate 15-25 minutes at 37oC;8. Add 50μL Stop Solution. Read at 450nm immediately. 表面活性物质关联蛋白A(SPA)检测试剂盒Test principleThe test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Surfactant Associated Protein A (SPA). Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated antibody specific to Surfactant Associated Protein A (SPA). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Surfactant Associated Protein A (SPA), biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Surfactant Associated Protein A (SPA) in the samples is then determined by comparing the O.D. of the samples to the standard curve.

克拉拉细胞蛋白16(CC16)检测试剂盒适用生物 Homo sapiens (Human，人) 检测范围 62.5-4000pg/mL 灵敏度 24.1pg/mL 样本类型 Serum, plasma, lung lavage fluid and other biological fluids. 实验时长 4.5h 实验方法 双抗夹心法  规格 96T克拉拉细胞蛋白16(CC16)检测试剂盒ELISA Kit for Clara Cell Protein 16 (CC16)FOR IN VITRO AND RESEARCH USE ONLY, NOT FOR USE IN CLINICAL DIAGNOSTIC PROCEDURES!Organism species     Homo sapiens (Human)    Product No.     SEA857Hu    Sample type     Serum, plasma, lung lavage fluid and other biological fluids.    Format     96-well strip plate    Assay length     4.5 hours    Detection range     62.5-4000pg/mL The standard curve concentrations used for the ELISA’s were 4000pg/mL, 2000pg/mL, 1000pg/mL, 500pg/mL, 250pg/mL, 125pg/mL, 62.5pg/mL    Sensitivity     The minimum detectable dose of this kit is typically less than 24.1pg/mL.    克拉拉细胞蛋白16(CC16)检测试剂盒SpecificityThis assay has high sensitivity and excellent specificity for detection of Clara Cell Protein 16 (CC16). No significant cross-reactivity or interference between Clara Cell Protein 16 (CC16) and analogues was observed.RecoveryMatrices listed below were spiked with certain level of recombinant Clara Cell Protein 16 (CC16) and the recovery rates were calculated by comparing the measured value to the expected amount of Clara Cell Protein 16 (CC16) in samples. Matrix     Recovery range (%)     Average(%)    serum(n=5)     80-88     84    EDTA plasma(n=5)     84-101     91    heparin plasma(n=5)     94-105     98    克拉拉细胞蛋白16(CC16)检测试剂盒PrecisionIntra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Clara Cell Protein 16 (CC16) were tested 20 times on one plate, respectively. Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Clara Cell Protein 16 (CC16) were tested on 3 different plates, 8 replicates in each plate. CV(%) = SD/meanX100 Intra-Assay: CVInter-Assay: CVLinearityThe linearity of the kit was assayed by testing samples spiked with appropriate concentration of Clara Cell Protein 16 (CC16) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected. Sample     1:2     1:4     1:8     1:16    serum(n=5)     83-97%     78-95%     92-101%     92-99%    EDTA plasma(n=5)     81-97%     78-98%     95-103%     79-103%    heparin plasma(n=5)     83-101%     88-102%     84-98%     78-97%    克拉拉细胞蛋白16(CC16)检测试剂盒StabilityThe stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition. To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.Reagents and materials providedReagents     Quantity     Reagents     Quantity    Pre-coated, ready to use 96-well strip plate     1     Plate sealer for 96 wells     4    Standard     2     Standard Diluent     1×20mL    Detection Reagent A     1×120μL     Assay Diluent A     1×12mL    Detection Reagent B     1×120μL     Assay Diluent B     1×12mL    TMB Substrate     1×9mL     Stop Solution     1×6mL    Wash Buffer (30 × concentrate)     1×20mL     Instruction manual     1    Assay procedure summary1. Prepare all reagents, samples and standards;2. Add 100μL standard or sample to each well. Incubate 2 hours at 37oC;3. Aspirate and add 100μL prepared Detection Reagent A. Incubate 1 hour at 37oC;4. Aspirate and wash 3 times;5. Add 100μL prepared Detection Reagent B. Incubate 30 minutes at 37oC;6. Aspirate and wash 5 times;7. Add 90μL Substrate Solution. Incubate 15-25 minutes at 37oC;8. Add 50μL Stop Solution. Read at 450nm immediately. 克拉拉细胞蛋白16(CC16)检测试剂盒Test principleThe test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Clara Cell Protein 16 (CC16). Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated antibody specific to Clara Cell Protein 16 (CC16). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Clara Cell Protein 16 (CC16), biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Clara Cell Protein 16 (CC16) in the samples is then determined by comparing the O.D. of the samples to the standard curve.

如果X与大部分晚期膀胱癌患者一样，她可能现在已经死了。在第一次确诊后，她接受了标准化疗。结果失败了。然后，她参加了一个药物临床试验，该药物最初被批准用于治疗其他肿瘤，但科学家希望知道，它是否能作用于转移性膀胱癌。结果似乎不行——参与试验的其他患者进展情况均不好。但X却好于预期。美国纽约纪念斯隆-凯特琳癌症中心（MSKCC）计算生物学家Barry Taylor表示，她的肿瘤完全消失了。X正是在该中心接受治疗。现在，5年多过去了，她依然健康且没有复发。X是一名特殊的响应者。这部分人十分稀少，他们对一种疗法有非常大的正响应，而这种疗法可能对其他大多数患者作用很小或毫无效果。这种响应并非仅限于癌症。例如，免疫学家已经发现了一些人艾滋病病毒测试呈阳性，但却没有艾滋病症状。显然，超级响应非常少见，这让科学家很难进行研究。他们轶事般的属性似乎能否定生物医学研究取得的统计结果。但在一项临床试验中，即便有若干超级响应者，一种药物也很难获得批准，因为它无法改变大多数患者的健康。这就意味着研究人员或药品企业缺少动机研究超级响应背后的机制。但当更多的癌症超级响应案例出现在出版的科学文献中，以及能在分子水平剖析患者情况的技术的出现，这种忽视情况开始被扭转。在X患者的案例中，基因序列揭示，她的肿瘤出现了一种突变，这也解释了她的癌症为何特别易受这种药物的攻击。这似乎能帮助研究人员预测其他患者对潜在疗法的响应。约翰斯·霍普金斯基墨尔癌症中心癌症专家Kenneth Kinzler说，这种相对较新的能力能综合描绘一个肿瘤的基因、转录组（基因表达）和代谢组（新陈代谢过程），以增加找到异常值背后原因的机会。超常特征马里兰州国立癌症研究所（NCI）的Barbara Conley表示，有关超级响应者的定义并非被普遍接受。Conley正在指导超级响应者创新项目（ERI），该项目旨在剖析这些患者的特征。ERI认为，当一个肿瘤消失，或者患者比其他接受同样治疗的人活的时间长90%，那么就出现了超级响应。对于难以治疗和晚期癌症而言，超级响应是指在至少6个月里，治疗使得肿瘤衰退至少30%，而接受同样治疗的患者的肿瘤仅衰退10%。例如，在X的病例中，她的肿瘤基因组中的结节性硬化综合征1基因出现了突变，该基因涉及调节细胞生长和增殖的通路。作用于X的药物能抑制该通路的信号。但这无法完全解释X出现超级响应的原因。针对与X共同参与试验的其他13个患者的肿瘤样本分析结果显示，4位患者也出现了同样的基因变异，但该药物仅让他们暂时缓解。为了更好地理解X和其他超级响应者，ERI希望对更大范围的参数进行全面分析，其中包括患者的病历、DNA变化、不同基因的RNA水平和新陈代谢通路。前MSKCC肿瘤学家Vincent Miller也指出，目前针对超级响应的观念正在改变，并认为应该寻找更多的这样的个体。现任基础医学公司首席医学官的Miller说，任何肿瘤学家都有少量患者在没有明显解释的条件下肿瘤消失了。

法国巴黎勒内？迪卡尔大学医学教授，INSERM（全国保健和医学研究院）院长，巴黎实体肿瘤功能基因组学的Jessica Zucman-Rossi博士和他的同事对欧洲患者中的肝硬化（F4，n = 118），纤维化（F2和F3中，n = 46）或非纤维化（F0和F1，n = 79）相关肿瘤样本进行了外显子组测序。根据HCC进展，肝硬化相关肿瘤表现为不同的阶段：7例发育不良性大分子期，7例早期，17例小分子进展期，58例经典型，29例预后不良性HCC。根据具体的风险因素，将肿瘤分为：明显酒精摄入型（41％），丙型肝炎病毒型（26％），非酒精性脂肪性肝炎型（18％），乙肝病毒型（14％），血色素沉着型（7％）和无已知病因型（11％）。通过测序确定了八种突变特征，其中6种（1A，1B，4，5，6和16）之前在一项泛癌症分析中进行了验证，而特征23和24为新型。在突变特征的基础上，分层聚类分析发现了六组（MSig1至6）和四种明显与饮酒/吸烟，黄曲霉毒素B1和其他风险因素相关的单独突变。研究人员还发现了161种与11个经常性途径相关的假定的驱动基因。三组基因----CTNNB1（酒精），TP53（HBV），和AXIN1之间存在突变关联。进一步的分析显示TERT启动子突变为肿瘤的早期事件，而FGF/CCND1扩增，TP53和CDKN2A改变，在侵袭性肿瘤更晚期开始出现。总体而言，28％的患者至少有一种损伤性改变（一种FDA批准的药物可以其为靶向），86％患者至少有一种曾在1期-3期临床试验中进行研究的损伤性改变。“测序已确定大量的基因，” Zucman-Rossi在她的介绍中说。“28%的患者拥有可能对治疗肝癌有益的基因。对于患者护理而言，确定靶基因中的基因组改变将有益于确定在未来试验中潜在收益于靶向治疗的肝癌患者。“ - Melinda Stevens

丙二醛(MDA)检测试剂盒适用生物 General，通用 检测范围 24.69-2000ng/mL 灵敏度 8.85ng/mL 样本类型 Serum, plasma and other biological fluids 实验时长 2.5h 实验方法 竞争抑制法  规格 96T 丙二醛(MDA)检测试剂盒ELISA Kit for Malondialdehyde (MDA)FOR IN VITRO AND RESEARCH USE ONLY, NOT FOR USE IN CLINICAL DIAGNOSTIC PROCEDURES!Organism species     General    Product No.     CEA597Ge    Sample type     Serum, plasma and other biological fluids    Format     96-well strip plate    Assay length     2.5 hours    Detection range     24.69-2000ng/mL The standard curve concentrations used for the ELISA’s were 2000ng/mL, 666.67ng/mL, 222.22ng/mL, 74.07ng/mL, 24.69ng/mL    Sensitivity     The minimum detectable dose of this kit is typically less than 8.85ng/mL.    SpecificityThis assay has high sensitivity and excellent specificity for detection of Malondialdehyde (MDA). No significant cross-reactivity or interference between Malondialdehyde (MDA) and analogues was observed.RecoveryMatrices listed below were spiked with certain level of recombinant Malondialdehyde (MDA) and the recovery rates were calculated by comparing the measured value to the expected amount of Malondialdehyde (MDA) in samples. Matrix     Recovery range (%)     Average(%)    serum(n=5)     93-101     96    EDTA plasma(n=5)     92-105     101    heparin plasma(n=5)     85-102     90    PrecisionIntra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Malondialdehyde (MDA) were tested 20 times on one plate, respectively. Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Malondialdehyde (MDA) were tested on 3 different plates, 8 replicates in each plate. CV(%) = SD/meanX100 Intra-Assay: CVInter-Assay: CVLinearityThe linearity of the kit was assayed by testing samples spiked with appropriate concentration of Malondialdehyde (MDA) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected. 丙二醛(MDA)检测试剂盒Sample     1:2     1:4     1:8     1:16    serum(n=5)     89-97%     87-99%     89-103%     78-97%    EDTA plasma(n=5)     83-99%     83-90%     80-101%     96-104%    heparin plasma(n=5)     86-95%     78-104%     90-101%     95-102%    StabilityThe stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition. To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.Reagents and materials providedReagents     Quantity     Reagents     Quantity    Pre-coated, ready to use 96-well strip plate     1     Plate sealer for 96 wells     4    Standard     2     Standard Diluent     1×20mL    Detection Reagent A     1     Assay Diluent A     1×12mL    Detection Reagent B     1×120μL     Assay Diluent B     1×12mL    Reagent Diluent     1×300μL     Stop Solution     1×6mL    TMB Substrate     1×9mL     Instruction manual     1    Wash Buffer (30 × concentrate)     1×20mL    Assay procedure summary1. Prepare all reagents, samples and standards;2. Add 50μL standard or sample to each well.    And then add 50μL prepared Detection Reagent A immediately.    Shake and mix. Incubate 1 hour at 37oC;3. Aspirate and wash 3 times;4. Add 100μL prepared Detection Reagent B. Incubate 30 minutes at 37oC;5. Aspirate and wash 5 times;6. Add 90μL Substrate Solution. Incubate 15-25 minutes at 37oC;7. Add 50μL Stop Solution. Read at 450 nm immediately.丙二醛(MDA)检测试剂盒Test principleThis assay employs the competitive inhibition enzyme immunoassay technique. A monoclonal antibody specific to Malondialdehyde (MDA) has been pre-coated onto a microplate. A competitive inhibition reaction is launched between biotin labeled Malondialdehyde (MDA) and unlabeled Malondialdehyde (MDA) (Standards or samples) with the pre-coated antibody specific to Malondialdehyde (MDA). After incubation the unbound conjugate is washed off. Next, avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. The amount of bound HRP conjugate is reverse proportional to the concentration of Malondialdehyde (MDA) in the sample. After addition of the substrate solution, the intensity of color developed is reverse proportional to the concentration of Malondialdehyde (MDA) in the sample.ELISA Kit for Malondialdehyde (MDA)FOR IN VITRO AND RESEARCH USE ONLY, NOT FOR USE IN CLINICAL DIAGNOSTIC PROCEDURES!Organism species     General    Product No.     CEA597Ge    Sample type     Serum, plasma and other biological fluids    Format     96-well strip plate    Assay length     2.5 hours    Detection range     24.69-2000ng/mL The standard curve concentrations used for the ELISA’s were 2000ng/mL, 666.67ng/mL, 222.22ng/mL, 74.07ng/mL, 24.69ng/mL    Sensitivity     The minimum detectable dose of this kit is typically less than 8.85ng/mL.    SpecificityThis assay has high sensitivity and excellent specificity for detection of Malondialdehyde (MDA). No significant cross-reactivity or interference between Malondialdehyde (MDA) and analogues was observed.RecoveryMatrices listed below were spiked with certain level of recombinant Malondialdehyde (MDA) and the recovery rates were calculated by comparing the measured value to the expected amount of Malondialdehyde (MDA) in samples. Matrix     Recovery range (%)     Average(%)    serum(n=5)     93-101     96    EDTA plasma(n=5)     92-105     101    heparin plasma(n=5)     85-102     90    PrecisionIntra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Malondialdehyde (MDA) were tested 20 times on one plate, respectively. Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Malondialdehyde (MDA) were tested on 3 different plates, 8 replicates in each plate. CV(%) = SD/meanX100 Intra-Assay: CVInter-Assay: CV丙二醛(MDA)检测试剂盒LinearityThe linearity of the kit was assayed by testing samples spiked with appropriate concentration of Malondialdehyde (MDA) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected. Sample     1:2     1:4     1:8     1:16    serum(n=5)     89-97%     87-99%     89-103%     78-97%    EDTA plasma(n=5)     83-99%     83-90%     80-101%     96-104%    heparin plasma(n=5)     86-95%     78-104%     90-101%     95-102%    StabilityThe stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition. To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.Reagents and materials providedReagents     Quantity     Reagents     Quantity    Pre-coated, ready to use 96-well strip plate     1     Plate sealer for 96 wells     4    Standard     2     Standard Diluent     1×20mL    Detection Reagent A     1     Assay Diluent A     1×12mL    Detection Reagent B     1×120μL     Assay Diluent B     1×12mL    Reagent Diluent     1×300μL     Stop Solution     1×6mL    TMB Substrate     1×9mL     Instruction manual     1    Wash Buffer (30 × concentrate)     1×20mL    Assay procedure summary1. Prepare all reagents, samples and standards;2. Add 50μL standard or sample to each well.    And then add 50μL prepared Detection Reagent A immediately.    Shake and mix. Incubate 1 hour at 37oC;3. Aspirate and wash 3 times;4. Add 100μL prepared Detection Reagent B. Incubate 30 minutes at 37oC;5. Aspirate and wash 5 times;6. Add 90μL Substrate Solution. Incubate 15-25 minutes at 37oC;7. Add 50μL Stop Solution. Read at 450 nm immediately.Test principleThis assay employs the competitive inhibition enzyme immunoassay technique. A monoclonal antibody specific to Malondialdehyde (MDA) has been pre-coated onto a microplate. A competitive inhibition reaction is launched between biotin labeled Malondialdehyde (MDA) and unlabeled Malondialdehyde (MDA) (Standards or samples) with the pre-coated antibody specific to Malondialdehyde (MDA). After incubation the unbound conjugate is washed off. Next, avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. The amount of bound HRP conjugate is reverse proportional to the concentration of Malondialdehyde (MDA) in the sample. After addition of the substrate solution, the intensity of color developed is reverse proportional to the concentration of Malondialdehyde (MDA) in the sample.

  2015上海沪震五一放假通知                                尊敬的客户，公司各职员：        您们好！感谢大家长期关注上海沪震生物动态，根据国家法定假期的规定，并结合公司实际情况，现对五一节放假做如下安排：一、放假时间5月1日至3日(星期五至星期天)放假，共3天。其中，5月1日(星期五)为五一假期，5月2日(星期六)，5月3日(星期天)为法定节假日照常公休。二、请公司各职员做好自己的节前工作安排。三、放假期间本公司不安排人员值班，如有订购产品请发送留言至我司网站平台，我们会在节后上班第一时间及时为您办理订货发货。各网站均有在线留言咨询栏。对此给您带来的不便我们深感抱歉。感谢你的支持与理解。                                                              上海沪震 特此通知! 

抗白蛋白抗体(AAA)检测试剂盒适用生物 Homo sapiens (Human，人) 检测范围 3.13-200ng/mL 灵敏度 1.27ng/mL 样本类型 Serum, plasma and other biological fluids. 实验时长 4h 实验方法 双抗夹心法  规格 96T 抗白蛋白抗体(AAA)检测试剂盒 ELISA Kit for Anti-Albumin Antibody (AAA)FOR IN VITRO AND RESEARCH USE ONLY, NOT FOR USE IN CLINICAL DIAGNOSTIC PROCEDURES!Organism species Homo sapiens (Human) Product No. AEB028Hu Sample type Serum, plasma and other biological fluids. Format 96-well strip plate Assay length 4 hours Detection range 3.13-200ng/mL The standard curve concentrations used for the ELISA’s were 200ng/mL, 100ng/mL, 50ng/mL, 25ng/mL, 12.5ng/mL, 6.25ng/mL, 3.13ng/mL  Sensitivity The minimum detectable dose of this kit is typically less than 1.27ng/mL.抗白蛋白抗体(AAA)检测试剂盒 SpecificityThis assay has high sensitivity and excellent specificity for detection of Anti-Albumin Antibody (AAA). No significant cross-reactivity or interference between Anti-Albumin Antibody (AAA) and analogues was observed. RecoveryMatrices listed below were spiked with certain level of Anti-Albumin Antibody (AAA) and the recovery rates were calculated by comparing the measured value to the expected amount of Anti-Albumin Antibody (AAA) in samples. Matrix Recovery range (%) Average(%) serum(n=5) 79-93 87 EDTA plasma(n=5) 92-101 97 heparin plasma(n=5) 80-103 101 PrecisionIntra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Anti-Albumin Antibody (AAA) were tested 20 times on one plate, respectively. Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Anti-Albumin Antibody (AAA) were tested on 3 different plates, 8 replicates in each plate. CV(%) = SD/meanX100 Intra-Assay: CVInter-Assay: CV抗白蛋白抗体(AAA)检测试剂盒 LinearityThe linearity of the kit was assayed by testing samples spiked with appropriate concentration of Anti-Albumin Antibody (AAA) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected. Sample 1:2 1:4 1:8 1:16 serum(n=5) 89-103% 94-102% 83-103% 80-91% EDTA plasma(n=5) 85-97% 95-105% 89-102% 93-105% heparin plasma(n=5) 87-101% 91-101% 81-103% 90-102% StabilityThe stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition. To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end. Reagents and materials providedReagents Quantity Reagents Quantity Pre-coated, ready to use 96-well strip plate 1 Plate sealer for 96 wells 4 Standard 2 Standard Diluent 1×20mL Detection Reagent A 1×120μL Assay Diluent A 1×12mL TMB Substrate 1×9mL Stop Solution 1×6mL Wash Buffer (30 × concentrate) 1×20mL Instruction manual 1 Assay procedure summary1. Prepare all reagents, samples and standards;2. Add 100μL standard or sample to each well. Incubate 2 hours at 37oC;3. Aspirate and add 100μL prepared Detection Reagent A. Incubate 1 hour at 37oC;4. Aspirate and wash 5 times;5. Add 90μL Substrate Solution. Incubate 15-25 minutes at 37oC;6. Add 50μL Stop Solution. Read at 450nm immediately. Test principleThe microtiter plate provided in this kit has been pre-coated with an antigen. Standards or samples are then added to the appropriate microtiter plate wells with a Horseradish Peroxidase (HRP)-conjugated secondary antibody. After TMB substrate solution is added, those wells that contain Anti-Albumin Antibody (AAA) will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Anti-Albumin Antibody (AAA) in the samples is then determined by comparing the O.D. of the samples to the standard curve.

不均一核糖核蛋白A2/B1(HNRPA2B1)检测试剂盒适用生物 Homo sapiens (Human，人) 检测范围 0.156-10ng/mL 灵敏度 0.057ng/mL 样本类型 Tissue homogenates and other biological fluids. 实验时长 4.5h 实验方法 双抗夹心法  规格 96T 不均一核糖核蛋白A2/B1(HNRPA2B1)检测试剂盒 ELISA Kit for Heterogeneous Nuclear Ribonucleoprotein A2/B1 (HNRPA2B1)FOR IN VITRO AND RESEARCH USE ONLY, NOT FOR USE IN CLINICAL DIAGNOSTIC PROCEDURES!Organism species Homo sapiens (Human) Product No. SEA323Hu Sample type Tissue homogenates and other biological fluids. Format 96-well strip plate Assay length 4.5 hours Detection range 0.156-10ng/mL The standard curve concentrations used for the ELISA’s were 10ng/mL, 5ng/mL, 2.5ng/mL, 1.25ng/mL, 0.625ng/mL, 0.313ng/mL, 0.156ng/mL  Sensitivity The minimum detectable dose of this kit is typically less than 0.057ng/mL.不均一核糖核蛋白A2/B1(HNRPA2B1)检测试剂盒  SpecificityThis assay has high sensitivity and excellent specificity for detection of Heterogeneous Nuclear Ribonucleoprotein A2/B1 (HNRPA2B1). No significant cross-reactivity or interference between Heterogeneous Nuclear Ribonucleoprotein A2/B1 (HNRPA2B1) and analogues was observed. PrecisionIntra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Heterogeneous Nuclear Ribonucleoprotein A2/B1 (HNRPA2B1) were tested 20 times on one plate, respectively. Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Heterogeneous Nuclear Ribonucleoprotein A2/B1 (HNRPA2B1) were tested on 3 different plates, 8 replicates in each plate. CV(%) = SD/meanX100 Intra-Assay: CVInter-Assay: CV不均一核糖核蛋白A2/B1(HNRPA2B1)检测试剂盒 StabilityThe stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition. To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end. Reagents and materials providedReagents Quantity Reagents Quantity Pre-coated, ready to use 96-well strip plate 1 Plate sealer for 96 wells 4 Standard 2 Standard Diluent 1×20mL Detection Reagent A 1×120μL Assay Diluent A 1×12mL Detection Reagent B 1×120μL Assay Diluent B 1×12mL TMB Substrate 1×9mL Stop Solution 1×6mL Wash Buffer (30 × concentrate) 1×20mL Instruction manual 1 Assay procedure summary1. Prepare all reagents, samples and standards;2. Add 100μL standard or sample to each well. Incubate 2 hours at 37oC;3. Aspirate and add 100μL prepared Detection Reagent A. Incubate 1 hour at 37oC;4. Aspirate and wash 3 times;5. Add 100μL prepared Detection Reagent B. Incubate 30 minutes at 37oC;6. Aspirate and wash 5 times;7. Add 90μL Substrate Solution. Incubate 15-25 minutes at 37oC;8. Add 50μL Stop Solution. Read at 450nm immediately. Test principleThe test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Heterogeneous Nuclear Ribonucleoprotein A2/B1 (HNRPA2B1). Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated antibody specific to Heterogeneous Nuclear Ribonucleoprotein A2/B1 (HNRPA2B1). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Heterogeneous Nuclear Ribonucleoprotein A2/B1 (HNRPA2B1), biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Heterogeneous Nuclear Ribonucleoprotein A2/B1 (HNRPA2B1) in the samples is then determined by comparing the O.D. of the samples to the standard curve.

瑞士药物监管局(Swissmedic)对多家可提供活细胞疗法的医疗机构发起刑事诉讼。药监局认为，这些机构的用药并未获得相关许可，而且会引发很高的健康风险。很长时间以来，瑞士的医院和私人诊所一直在提供所谓的“活细胞”(Frischzellen)治疗方法(羊胎素)。这受到了来自中国、俄罗斯和近东游客的追捧。但其治疗过程中所使用的产品，却并未获得许可，且可能引发很高的健康风险。瑞士联邦卫生部(BAG)(英、德、法、意)和瑞士药物监管局(Swissmedic)(英、德、法、意)连同各州共同决定，今后这类部门需申请批准或许可，才可继续使用同类药物。瑞士药物监管局监管委员会主任Christian Sch？rer先生对瑞士资讯swissinfo.ch的记者表示，针对目前部分机构的违规行为，正在进行调查。调查主要集中在沃州，还有瓦莱州和阿彭策尔州，其他州应该也有，但并没有上报。调查名单尚不能公开，不过名单上的35家医疗机构，有一半已确认并未与活细胞治疗方法有染，但其网页必须进行整改。何为“打羊胎素”这类“不合法”(illegale)的活细胞治疗方法是指给患者体内注射羊胚胎(Schafsf？ten，3个月以上)或羊胎盘(Schafsplazenta)的细胞及细胞成分(俗称打羊胎素)，并许诺可延缓衰老。那么，之前所有号称来瑞士打羊胎素的，都是不合法的吗？Sch？rer先生这样回答了瑞士资讯swissinfo.ch记者的问题：“如前所述，我们的行动是清查这些医疗机构所提供的药物，是否是涉及动物细胞的传统活细胞诊疗方式(将动物活细胞注入人体)，到目前为止，我们尚未发现一家；但是，有使用动物物质的，这今后需要申请许可”。许可真的可以申请到吗？“和所有药物一样，如果是认真研发的、证明有药效的，就可以获得许可，”Sch？rer说。瑞士卫生机构称，欲提供活细胞疗法的医疗机构，需依照所提供药物的种类，分别向瑞士药监局或联邦卫生部申请相关许可。根据瑞士法律(德、法、意)，活细胞疗法如采用的是活体细胞，则属于异种移植(Xenotransplantation)，应遵从移植法(Transplantationsgesetz)，需要向联邦卫生部申请许可。这类管理很严格，因为要避免动物病原体感染人类。如不采用活体细胞，则属于药物，受药物法(Heilmittelgesetz，简称：HMG)监管。但瑞士联邦特意强调：至今为止，瑞士没有向任何一家机构颁发过活细胞医疗许可。

瑞士药物监管局(Swissmedic)对多家可提供活细胞疗法的医疗机构发起刑事诉讼。药监局认为，这些机构的用药并未获得相关许可，而且会引发很高的健康风险。很长时间以来，瑞士的医院和私人诊所一直在提供所谓的“活细胞”(Frischzellen)治疗方法(羊胎素)。这受到了来自中国、俄罗斯和近东游客的追捧。但其治疗过程中所使用的产品，却并未获得许可，且可能引发很高的健康风险。瑞士联邦卫生部(BAG)(英、德、法、意)和瑞士药物监管局(Swissmedic)(英、德、法、意)连同各州共同决定，今后这类部门需申请批准或许可，才可继续使用同类药物。瑞士药物监管局监管委员会主任Christian Sch？rer先生对瑞士资讯swissinfo.ch的记者表示，针对目前部分机构的违规行为，正在进行调查。调查主要集中在沃州，还有瓦莱州和阿彭策尔州，其他州应该也有，但并没有上报。调查名单尚不能公开，不过名单上的35家医疗机构，有一半已确认并未与活细胞治疗方法有染，但其网页必须进行整改。何为“打羊胎素”这类“不合法”(illegale)的活细胞治疗方法是指给患者体内注射羊胚胎(Schafsf？ten，3个月以上)或羊胎盘(Schafsplazenta)的细胞及细胞成分(俗称打羊胎素)，并许诺可延缓衰老。那么，之前所有号称来瑞士打羊胎素的，都是不合法的吗？Sch？rer先生这样回答了瑞士资讯swissinfo.ch记者的问题：“如前所述，我们的行动是清查这些医疗机构所提供的药物，是否是涉及动物细胞的传统活细胞诊疗方式(将动物活细胞注入人体)，到目前为止，我们尚未发现一家；但是，有使用动物物质的，这今后需要申请许可”。许可真的可以申请到吗？“和所有药物一样，如果是认真研发的、证明有药效的，就可以获得许可，”Sch？rer说。瑞士卫生机构称，欲提供活细胞疗法的医疗机构，需依照所提供药物的种类，分别向瑞士药监局或联邦卫生部申请相关许可。根据瑞士法律(德、法、意)，活细胞疗法如采用的是活体细胞，则属于异种移植(Xenotransplantation)，应遵从移植法(Transplantationsgesetz)，需要向联邦卫生部申请许可。这类管理很严格，因为要避免动物病原体感染人类。如不采用活体细胞，则属于药物，受药物法(Heilmittelgesetz，简称：HMG)监管。但瑞士联邦特意强调：至今为止，瑞士没有向任何一家机构颁发过活细胞医疗许可。

项新的合作研究描述了肺组织损伤后再生的方式。再生的细胞并不是典型的干细胞，而是成熟的肺细胞在响应伤害时做出的反应。来自宾夕法尼亚大学和杜克大学的研究人员发现，证实肺组织的修复比原来所认为的更加灵巧。这篇研究成果发表在最新的Nature Communications。肺泡中的两种呼吸道细胞具有非常不同的功能。长而细的1型细胞，是气体（氧气和二氧化碳）交换的场所。2型细胞分泌表面活性剂，有助于保持气道开放。研究人员在小鼠模型中发现这两种类型的细胞拥有相同的前体干细胞起源。接下来，研究小组在小鼠模型中取出部分肺组织并进行单细胞培养，以研究肺细胞再生的可塑性。他们发现，1型细胞可以变成2型细胞，反之亦然。杜克大学的研究小组之前已经阐述过2型细胞有在成年小鼠充当祖细胞的功能，可分化成气体交换型的1细胞。不过没有报道1型细胞也有类似的能力。于是他们决定测试1型细胞，并发现大约三周后，1型细胞在各种再生模型下，都转变为2型细胞，新的细胞填充了被损伤的肺区域。这个过程随后被证实与TGFβ信号调控有关。这是第一次研究表明一种已经分化充分的细胞可以在适当的条件下，恢复到以前的状态。而这种情况，不是通过转录因子的特殊作用，是通过诱导损伤，产生自我修复信号。研究小组还在文章中概述了肠道和皮肤中的干细胞维持和分化的基本思路，和心脏组织细胞的类似机制。他们希望这方面的知识能应用到其他肺部疾病如急性呼吸窘迫综合征和特发性肺纤维化，找到在肺泡病变时产生新肺泡细胞的办法。

水通道蛋白5(AQP5)检测试剂盒适用生物 Homo sapiens (Human，人) 检测范围 0.156-10ng/mL 灵敏度 0.065ng/mL 样本类型 Tissue homogenates, cell lysates and other biological fluids. 实验时长 4.5h 实验方法 双抗夹心法  规格 96T水通道蛋白5(AQP5)检测试剂盒(酶联免疫吸附试验法)适用生物：人使用说明书仅供体外研究使用，不用于临床诊断!水通道蛋白5(AQP5)检测试剂盒[预期应用]本试剂盒运用双抗体夹心ELISA 法定量测定人组织匀浆、细胞裂解液或其它相关生物液体中AQP5 含量。[试剂盒内容]试剂名称数量试剂名称数量96孔板(预包被) 1 96孔板覆膜4标准品2 标准品稀释液1×20mL检测溶液A 1×120μL 检测稀释液A 1×12mL检测溶液B 1×120μL 检测稀释液B 1×12mLTMB底物1×9mL 终止液1×6mL浓洗涤液(30×) 1×20mL 使用说明书1[需自备的设备及试剂]1、450±10nm 滤光片的酶标仪(建议仪器使用前提前预热)2、单道或多道微量加液器及吸头3、稀释样品的EP 管4、蒸馏水或去离子水5、吸水纸6、盛放洗液的容器[试剂盒的储存及有效期]1、未开封的试剂盒：所有试剂均按试剂瓶标签上所示保存。请注意，收到试剂盒后请尽快将标准品、检测溶液A、检测溶液B 以及96 孔板保存于-20oC。2、使用后的试剂盒：剩余试剂仍需按照试剂瓶标签所示的温度保存，开封后的酶标板要加干燥剂后密封保存于-20oC，避免潮湿。注意：试剂盒内酶标条可拆卸，按实验需求可分多次使用；使用后的剩余试剂盒建议在首次实验后1 个月内使用完毕。产品过期时间以盒子上的标签为准，保质期内所有组分都确保是稳定的。[标本的采集与保存]1、组织匀浆：1） 取适量组织块，于预冷PBS（0.01mol/L, pH 7.0-7.2）中清洗去除血液，称重后备用（组织块较大需先剪碎后再匀浆）；2） 可同时选用多种匀浆方法达到较好的破碎效果：首先将组织块移入玻璃匀浆器，加入5-10mL 预冷PBS 进行充分研磨，该过程需在冰上进行（有条件实验室可选用机器匀浆）；得到的匀浆液可再利用超声破碎或反复冻融进一步处理（超声破碎过程中注意冰浴降温；反复冻融法可重复2 次）。3） 将制备好的匀浆液于5000×g 离心5 分钟，留取上清即可检测。2、细胞裂解液：1）贴壁细胞需要先用胰酶消化，离心收集细胞（悬浮细胞可直接离心收集）；2）将收集到的细胞用冷PBS 洗3 次；3）物理方法裂解细胞（可先超声破碎细胞，再反复冻融）：i 超声破碎：取适量PBS 重悬细胞，用一定功率的超声波处理细胞悬液，使细胞急剧震荡破裂。ii 反复冻融：将待破碎的细胞在-20oC 以下冰冻，室温融解，反复3 次，使细胞溶胀破碎。4）将标本于2-8oC 1500×g 离心10 分钟，收集上清备用。3、其它生物标本：请1000×g 离心20 分钟，取上清即可检测，或将上清置于-20oC 或-80oC 保存，但应避免反复冻融。注意：1、以上标本均需密封保存，4oC 保存应小于1 周，-20oC 不应超过1 个月，-80oC 不应超过2 个月。2、标本溶血会影响最后检测结果，因此溶血标本不宜进行此项检测。3、标本使用前应缓慢均衡至室温，不应加热使之融解。[试剂准备]1、使用前将所有的试剂和标本缓慢均衡至室温(18-25oC)，试剂不能直接在37oC 溶解。2、标准品(冻干品)：每瓶标准品加入标准品稀释液1mL，盖好后室温静置大约10 分钟，同时反复颠倒/搓动以助溶解，其浓度为40ng/mL(贮液)。先将其稀释为10ng/mL(标准曲线最高浓度)后，再准备7 个稀释标准品的EP 管，每个EP 管中加入500μL 的标准品稀释液，如图所示依次倍比稀释成10ng/mL，5ng/mL，2.5ng/mL，1.25ng/mL，0.625ng/mL，0.312ng/mL，0.156ng/mL，标准品稀释液(0ng/mL)直接作为空白孔。为保证实验结果有效性，每次实验请使用新的标准品溶液。3、检测溶液A 及检测溶液B：Detection A 及Detection B 在使用前请手甩几下或少时离心处理，以使管壁或瓶盖的液体沉积到管底。临用前分别以检测稀释液A 或B1:100 稀释(如：10μL 检测溶液A/990μL 检测稀释液A)，充分混匀，稀释前根据预先计算好的每次实验所需的总量配制(100μL/孔)，实际配制时应多配制0.1-0.2mL。Tube 1 2 3 4 5 6 7 8 9ng/mL 40 10 5 2.5 1.25 0.625 0.312 0.156 04、浓洗涤液：用580mL 蒸馏水或去离子水将20mL 浓洗涤液稀释至600mL，进行30 倍稀释。5、底物溶液：请用灭菌的移液器吸头吸取所需体积的TMB 至另一干净容器中使用，容器中剩余的底物应予丢弃，不要倒回TMB 瓶中。注意：1、标准品的稀释不能直接在板中进行。2、标准品请于临用前15 分钟内配制。该标准品只能使用一次。3、标准品、检测溶液A 工作液、检测溶液B 工作液请使用相应的稀释液配制，不能混淆。混匀时要轻轻充分混匀，避免起泡。为保证实验结果的准确请使用微量吸管，并校准微量加液器。请依据所需的量精确配制，尽量不要微量配制(如吸取检测溶液A 时，一次不要小于10μL)，以避免造成浓度误差。4、请勿重复使用已经稀释过的标准品、检测溶液A 工作液和检测溶液B 工作液。5、浓洗涤液中如有结晶析出，请先温育至室温，轻轻混匀，至到结晶完全溶解再进行配制。6、试剂盒中部分试剂为储存液，客户需配置成工作液后使用，在配置过程中如因纯净水质量差或水质污染，以及实验中所用耗材洁净度差，可能造成实验结果不准确，甚至完全错误，请使用双蒸水。[标本处理]1、本公司只对试剂盒本身负责，不对因使用该试剂盒所造成的样本消耗负责，请使用者使用前充分考虑到样本的可能使用量，预留充足的样本。2、实验前应预测标本含量，如果标本浓度过高，应对标本进行稀释，使稀释后的标本符合试剂盒的检测范围，计算时再乘以相应的稀释倍数。标本使用0.01mol/L 的PBS 稀释(PH=7.0-7.2)。3、若所检样本不包含在说明书所列样本之中，建议进行预实验验证其有效性，并注意留存样本。4、使用化学裂解液制备的组织匀浆或细胞提取液可能会由于某些化学物质的引入导致ELISA 实验结果偏差。5、若样本为细胞培养上清，因该类样本干扰因素较多，如：细胞状态、细胞数量、采样时间等，所以可能存在检测不出的情况。6、某些天然蛋白或重组蛋白，包括原核及真核重组蛋白，可能因为与本产品所使用的检测抗体及捕获抗体不匹配，而不被检测出。7、建议使用新鲜样本，保存时间过长可能会存在蛋白降解或变性导致实验结果偏差。[操作步骤]1、加样：分别设标准孔、待测样品孔、空白孔。设标准孔7 孔，依次加入100μL 不同浓度的标准品(见试剂准备2)。空白孔加100μL(见试剂准备第二步最后一管)，余孔加待测样品100μL，酶标板加上覆膜，37oC 温育2 小时。2、弃去液体，甩干，不用洗涤。3、每孔加检测溶液A 工作液100μL(临用前配制)，酶标板加上覆膜，37oC 温育1 小时。4、弃去孔内液体，每孔用350μL 的洗涤液洗涤，浸泡1-2 分钟，吸去(不可触及板壁)或甩掉酶标板内的液体，在实验台上铺垫几层吸水纸，酶标板朝下用力拍几次(也可轻拍将孔内液体拍干)，重复洗板3 次。最后一次洗涤后，要把孔内的洗涤液完全甩干。自动洗板机亦可。5、每孔加检测溶液B 工作液(临用前配制)100μL，加上覆膜，37oC 温育30 分钟。6、弃去孔内液体，甩干，洗板5 次，方法同步骤4。7、每孔加底物溶液90μL，酶标板加上覆膜，37oC 避光显色(反应时间控制在15-25 分钟，不要超过30 分钟。当标准孔的前3-4 孔有明显的梯度蓝色，后3-4 孔梯度不明显时，即可终止)。8、每孔加终止溶液50μL，终止反应，此时蓝色立转黄色。终止液的加入顺序应尽量与底物溶液的加入顺序相同。如出现颜色不匀一，请轻轻晃动酶标板以使溶液混合均匀。9、在确保酶标板底无水滴及孔内无气泡后，立即用酶标仪在450nm 波长测量各孔的光密度(O.D.值)。注意：1、试剂准备：准备一次实验所需要的酶标条，其它的可从微孔板上拆下，密封，按照说明书要求保存，以备下次使用。2、加样：实验操作中请使用一次性的吸头，避免交叉污染。加样时注意不要有气泡，将样品加于酶标板底部，尽量不触及孔壁，轻轻晃动混匀。加样或加试剂时，第一个孔与最后一个孔加样之间的时间间隔如果太大，将会导致不同的“预温育”时间，从而明显地影响到测量值的准确性及重复性。因此，一次加样时间(包括标准品及所有样品)最好控制在10 分钟内。推荐设置复孔进行实验。3、温育：为防止样品蒸发，实验时请将加上盖或覆膜的酶标板置于湿盒内，以避免液体蒸发，洗板后应尽快进行下步操作，任何时侯都应避免酶标板处于干燥状态，同时应严格遵守给定的温育时间和温度。4、洗涤：充分的洗涤非常重要，在每次洗涤过程中，都要将洗涤液完全甩干。洗涤过程中反应孔中残留的洗涤液应在滤纸上拍干，勿将滤纸直接放入反应孔中吸水，同时要消除板底残留的液体和手指印，避免影响最后的酶标仪读数。如果有自动洗板机，应在熟练使用后再用到正式实验过程中。5、反应时间的控制：加入底物后请定时观察反应孔的颜色变化(比如，每隔10 分钟观察一次)，如颜色较深，请提前加入终止液终止反应，避免反应过强从而影响酶标仪光密度读数。6、底物：底物请避光保存，在储存和温育时避免强光直接照射。7、如果实验室内湿度低于60%，推荐使用加湿器提高湿度水平。[实验原理]将AQP5 抗体包被于96 孔微孔板中，制成固相载体，向微孔中分别加入标准品或标本，其中的AQP5 与连接于固相载体上的抗体结合，然后加入生物素化的AQP5 抗体，将未结合的生物素化抗体洗净后，加入HRP 标记的亲和素，再次彻底洗涤后加入TMB 底物显色。TMB 在过氧化物酶的催化下转化成蓝色，并在酸的作用下转化成最终的黄色。颜色的深浅和样品中的AQP5 呈正相关。用酶标仪在450nm 波长下测定吸光度(O.D.值)，计算样品浓度。[计算]各标准品及样本O.D.值扣除空白孔O.D.值后作图(七点图)，如设置复孔，则应取其平均值计算。以标准品的浓度为纵坐标(或对数坐标)，O.D.值为横坐标(或对数坐标），绘出标准曲线(最佳方程式应依回归方程计算的R2值来定，以R2 值越趋近于1 为好)。推荐使用专业制作曲线软件进行分析，如curve expert 1.30，根据样品O.D.值，由标准曲线查出相应的浓度，乘以稀释倍数；或用标准物的浓度与O.D.值计算出标准曲线的回归方程式，将样品的O.D.值代入方程式，计算出样品浓度，再乘以稀释倍数，即为样品的实际浓度。 

水通道蛋白4(AQP4)检测试剂盒适用生物 Homo sapiens (Human，人) 检测范围 62.5-4000pg/mL 灵敏度 27.9pg/mL 样本类型 Serum, plasma, tissue homogenates and other biological fluids. 实验时长 4.5h 实验方法 双抗夹心法  规格 96T水通道蛋白4(AQP4)检测试剂盒(酶联免疫吸附试验法)适用生物：人使用说明书仅供体外研究使用，不用于临床诊断!水通道蛋白4(AQP4)检测试剂盒[预期应用]本试剂盒运用双抗体夹心ELISA 法定量测定人血清、血浆、组织匀浆或其它相关生物液体中AQP4 含量。[试剂盒内容]试剂名称数量试剂名称数量96孔板(预包被) 1 96孔板覆膜4标准品2 标准品稀释液1×20mL检测溶液A 1×120μL 检测稀释液A 1×12mL检测溶液B 1×120μL 检测稀释液B 1×12mLTMB底物1×9mL 终止液1×6mL浓洗涤液(30×) 1×20mL 使用说明书1[需自备的设备及试剂]1、450±10nm 滤光片的酶标仪(建议仪器使用前提前预热)2、单道或多道微量加液器及吸头3、稀释样品的EP 管4、蒸馏水或去离子水5、吸水纸6、盛放洗液的容器[试剂盒的储存及有效期]1、未开封的试剂盒：所有试剂均按试剂瓶标签上所示保存。请注意，收到试剂盒后请尽快将标准品、检测溶液A、检测溶液B 以及96 孔板保存于-20oC。2、使用后的试剂盒：剩余试剂仍需按照试剂瓶标签所示的温度保存，开封后的酶标板要加干燥剂后密封保存于-20oC，避免潮湿。注意：试剂盒内酶标条可拆卸，按实验需求可分多次使用；使用后的剩余试剂盒建议在首次实验后1 个月内使用完毕。产品过期时间以盒子上的标签为准，保质期内所有组分都确保是稳定的。[标本的采集与保存]1、血清：将收集于血清分离管的全血标本在室温放置2 小时或4oC 过夜，然后1000×g 离心20 分钟，取上清即可，或将上清置于-20oC 或-80oC 保存，但应避免反复冻融。2、血浆：用EDTA 或肝素作为抗凝剂采集标本，并将标本在采集后的30 分钟内于2-8oC 1000×g 离心15 分钟，取上清即可检测，或将上清置于-20oC 或-80oC 保存，但应避免反复冻融。3、组织匀浆：1） 取适量组织块，于预冷PBS（0.01mol/L, pH 7.0-7.2）中清洗去除血液，称重后备用（组织块较大需先剪碎后再匀浆）；2） 可同时选用多种匀浆方法达到较好的破碎效果：首先将组织块移入玻璃匀浆器，加入5-10mL 预冷PBS 进行充分研磨，该过程需在冰上进行（有条件实验室可选用机器匀浆）；得到的匀浆液可再利用超声破碎或反复冻融进一步处理（超声破碎过程中注意冰浴降温；反复冻融法可重复2 次）。3） 将制备好的匀浆液于5000×g 离心5 分钟，留取上清即可检测。4、其它生物标本：请1000×g 离心20 分钟，取上清即可检测，或将上清置于-20oC 或-80oC 保存，但应避免反复冻融。注意：1、以上标本均需密封保存，4oC 保存应小于1 周，-20oC 不应超过1 个月，-80oC 不应超过2 个月。2、标本溶血会影响最后检测结果，因此溶血标本不宜进行此项检测。3、标本使用前应缓慢均衡至室温，不应加热使之融解。[试剂准备]1、使用前将所有的试剂和标本缓慢均衡至室温(18-25oC)，试剂不能直接在37oC 溶解。2、标准品(冻干品)：每瓶标准品加入标准品稀释液1mL，盖好后室温静置大约10 分钟，同时反复颠倒/搓动以助溶解，其浓度为20,000pg/mL(贮液)。先将其稀释为4,000pg/mL(标准曲线最高浓度)后，再准备7 个稀释标准品的EP 管，每个EP 管中加入500μL 的标准品稀释液，如图所示依次倍比稀释成4,000pg/mL,2,000pg/mL, 1,000pg/mL, 500pg/mL, 250pg/mL, 125pg/mL, 62.5pg/mL，标准品稀释液(0pg/mL)直接作为空白孔。为保证实验结果有效性，每次实验请使用新的标准品溶液。3、检测溶液A 及检测溶液B：Detection A 及Detection B 在使用前请手甩几下或少时离心处理，以使管壁或瓶盖的液体沉积到管底。临用前分别以检测稀释液A 或B1:100 稀释(如：10μL 检测溶液A/990μL 检测稀释液A)，充分混匀，稀释前根据预先计算好的每次实验所需的总量配制(100μL/孔)，实际配制时应多配制0.1-0.2mL。4、浓洗涤液：用580mL 蒸馏水或去离子水将20mL 浓洗涤液稀释至600mL，进行30 倍稀释。5、底物溶液：请用灭菌的移液器吸头吸取所需体积的TMB 至另一干净容器中使用，容器中剩余的底物应予丢弃，不要倒回TMB 瓶中。注意：1、标准品的稀释不能直接在板中进行。2、标准品请于临用前15 分钟内配制。该标准品只能使用一次。3、标准品、检测溶液A 工作液、检测溶液B 工作液请使用相应的稀释液配制，不能混淆。混匀时要轻轻充分混匀，避免起泡。为保证实验结果的准确请使用微量吸管，并校准微量加液器。请依据所需的量精确配制，尽量不要微量配制(如吸取检测溶液A 时，一次不要小于10μL)，以避免造成浓度误差。Tube 1 2 3 4 5 6 7 8 9pg/mL 20,000 4,000 2,000 1,000 500 250 125 62.5 04、请勿重复使用已经稀释过的标准品、检测溶液A 工作液和检测溶液B 工作液。5、浓洗涤液中如有结晶析出，请先温育至室温，轻轻混匀，至到结晶完全溶解再进行配制。6、试剂盒中部分试剂为储存液，客户需配置成工作液后使用，在配置过程中如因纯净水质量差或水质污染，以及实验中所用耗材洁净度差，可能造成实验结果不准确，甚至完全错误，请使用双蒸水。[标本处理]1、本公司只对试剂盒本身负责，不对因使用该试剂盒所造成的样本消耗负责，请使用者使用前充分考虑到样本的可能使用量，预留充足的样本。2、实验前应预测标本含量，如果标本浓度过高，应对标本进行稀释，使稀释后的标本符合试剂盒的检测范围，计算时再乘以相应的稀释倍数。3、血清或血浆标本推荐稀释大约100 倍，如：稀释100 倍，取10μL 血清或血浆加入990μL PBS。标本使用0.01mol/L 的PBS 稀释(PH=7.0-7.2)。4、若所检样本不包含在说明书所列样本之中，建议进行预实验验证其有效性，并注意留存样本。5、使用化学裂解液制备的组织匀浆或细胞提取液可能会由于某些化学物质的引入导致ELISA 实验结果偏差。6、若样本为细胞培养上清，因该类样本干扰因素较多，如：细胞状态、细胞数量、采样时间等，所以可能存在检测不出的情况。7、某些天然蛋白或重组蛋白，包括原核及真核重组蛋白，可能因为与本产品所使用的检测抗体及捕获抗体不匹配，而不被检测出。8、建议使用新鲜样本，保存时间过长可能会存在蛋白降解或变性导致实验结果偏差。[操作步骤]1、加样：分别设标准孔、待测样品孔、空白孔。设标准孔7 孔，依次加入100μL 不同浓度的标准品(见试剂准备2)。空白孔加100μL(见试剂准备第二步最后一管)，余孔加待测样品100μL，酶标板加上覆膜，37oC 温育2 小时。2、弃去液体，甩干，不用洗涤。

水通道蛋白3(AQP3)检测试剂盒适用生物 Homo sapiens (Human，人)  检测范围 0.156-10ng/mL 灵敏度 0.063ng/mL 样本类型 Serum, plasma, tissue homogenates and other biological fluids. 实验时长 4.5h 实验方法 双抗夹心法  规格 96T水通道蛋白3(AQP3)检测试剂盒(酶联免疫吸附试验法)适用生物：人使用说明书仅供体外研究使用，不用于临床诊断![预期应用]本试剂盒运用双抗体夹心ELISA 法定量测定人血清、血浆、组织匀浆或其它相关生物液体中AQP3 含量。[试剂盒内容]试剂名称数量试剂名称数量96孔板(预包被) 1 96孔板覆膜4标准品2 标准品稀释液1×20mL检测溶液A 1×120μL 检测稀释液A 1×12mL检测溶液B 1×120μL 检测稀释液B 1×12mLTMB底物1×9mL 终止液1×6mL浓洗涤液(30×) 1×20mL 使用说明书1[需自备的设备及试剂]1、450±10nm 滤光片的酶标仪(建议仪器使用前提前预热)2、单道或多道微量加液器及吸头3、稀释样品的EP 管4、蒸馏水或去离子水5、吸水纸6、盛放洗液的容器[试剂盒的储存及有效期]1、未开封的试剂盒：所有试剂均按试剂瓶标签上所示保存。请注意，收到试剂盒后请尽快将标准品、检测溶液A、检测溶液B 以及96 孔板保存于-20oC。2、使用后的试剂盒：剩余试剂仍需按照试剂瓶标签所示的温度保存，开封后的酶标板要加干燥剂后密封保存于-20oC，避免潮湿。注意：试剂盒内酶标条可拆卸，按实验需求可分多次使用；使用后的剩余试剂盒建议在首次实验后1 个月内使用完毕。产品过期时间以盒子上的标签为准，保质期内所有组分都确保是稳定的。[标本的采集与保存]1、血清：将收集于血清分离管的全血标本在室温放置2 小时或4oC 过夜，然后1000×g 离心20 分钟，取上清即可，或将上清置于-20oC 或-80oC 保存，但应避免反复冻融。2、血浆：用EDTA 或肝素作为抗凝剂采集标本，并将标本在采集后的30 分钟内于2-8oC 1000×g 离心15 分钟，取上清即可检测，或将上清置于-20oC 或-80oC 保存，但应避免反复冻融。3、组织匀浆：1） 取适量组织块，于预冷PBS（0.01mol/L, pH 7.0-7.2）中清洗去除血液，称重后备用（组织块较大需先剪碎后再匀浆）；2） 可同时选用多种匀浆方法达到较好的破碎效果：首先将组织块移入玻璃匀浆器，加入5-10mL 预冷PBS 进行充分研磨，该过程需在冰上进行（有条件实验室可选用机器匀浆）；得到的匀浆液可再利用超声破碎或反复冻融进一步处理（超声破碎过程中注意冰浴降温；反复冻融法可重复2 次）。3） 将制备好的匀浆液于5000×g 离心5 分钟，留取上清即可检测。4、其它生物标本：请1000×g 离心20 分钟，取上清即可检测，或将上清置于-20oC 或-80oC 保存，但应避免反复冻融。注意：1、以上标本均需密封保存，4oC 保存应小于1 周，-20oC 不应超过1 个月，-80oC 不应超过2 个月。2、标本溶血会影响最后检测结果，因此溶血标本不宜进行此项检测。3、标本使用前应缓慢均衡至室温，不应加热使之融解。[试剂准备]1、使用前将所有的试剂和标本缓慢均衡至室温(18-25oC)，试剂不能直接在37oC 溶解。2、标准品(冻干品)：每瓶标准品加入标准品稀释液1mL，盖好后室温静置大约10 分钟，同时反复颠倒/搓动以助溶解，其浓度为20ng/mL(贮液)。先将其稀释为10ng/mL(标准曲线最高浓度)后，再准备7 个稀释标准品的EP 管，每个EP 管中加入500μL 的标准品稀释液，如图所示依次倍比稀释成10ng/mL，5ng/mL，2.5ng/mL，1.25ng/mL，0.625ng/mL，0.312ng/mL，0.156ng/mL，标准品稀释液(0ng/mL)直接作为空白孔。为保证实验结果有效性，每次实验请使用新的标准品溶液。3、检测溶液A 及检测溶液B：Detection A 及Detection B 在使用前请手甩几下或少时离心处理，以使管壁或瓶盖的液体沉积到管底。临用前分别以检测稀释液A 或B1:100 稀释(如：10μL 检测溶液A/990μL 检测稀释液A)，充分混匀，稀释前根据预先计算好的每次实验所需的总量配制(100μL/孔)，实际配制时应多配制0.1-0.2mL。4、浓洗涤液：用580mL 蒸馏水或去离子水将20mL 浓洗涤液稀释至600mL，进行30 倍稀释。5、底物溶液：请用灭菌的移液器吸头吸取所需体积的TMB 至另一干净容器中使用，容器中剩余的底物应予丢弃，不要倒回TMB 瓶中。注意：1、标准品的稀释不能直接在板中进行。2、标准品请于临用前15 分钟内配制。该标准品只能使用一次。3、标准品、检测溶液A 工作液、检测溶液B 工作液请使用相应的稀释液配制，不能混淆。混匀时要轻轻充分混匀，避免起泡。为保证实验结果的准确请使用微量吸管，并校准微量加液器。请依据所需的量精确配制，尽量不要微量配制(如吸取检测溶液A 时，一次不要小于10μL)，以避免造成浓度误差。Tube 1 2 3 4 5 6 7 8 9ng/mL 20 10 5 2.5 1.25 0.625 0.312 0.156 04、请勿重复使用已经稀释过的标准品、检测溶液A 工作液和检测溶液B 工作液。5、浓洗涤液中如有结晶析出，请先温育至室温，轻轻混匀，至到结晶完全溶解再进行配制。6、试剂盒中部分试剂为储存液，客户需配置成工作液后使用，在配置过程中如因纯净水质量差或水质污染，以及实验中所用耗材洁净度差，可能造成实验结果不准确，甚至完全错误，请使用双蒸水。

胶质细胞系来源神经营养因子(GDNF)检测试剂盒适用生物     Homo sapiens (Human，人)    检测范围     0.156-10ng/mL     灵敏度     0.062ng/mL    样本类型     Serum, plasma, tissue homogenates, cell lysates, cerebrospinal fluid, cell culture supernates and other biological fluids.    实验时长     4.5h     实验方法     双抗夹心法       规格     96T    胶质细胞系来源神经营养因子(GDNF)检测试剂盒(酶联免疫吸附试验法)适用生物：人使用说明书仅供体外研究使用，不用于临床诊断!胶质细胞系来源神经营养因子(GDNF)检测试剂盒[预期应用]本试剂盒运用双抗体夹心ELISA 法定量测定人血清、血浆、组织匀浆、细胞裂解液、脑脊液、细胞培养上清或其它相关生物液体中GDNF 含量。[试剂盒内容]试剂名称数量试剂名称数量96孔板(预包被) 1 96孔板覆膜4标准品2 标准品稀释液1×20mL检测溶液A 1×120μL 检测稀释液A 1×12mL检测溶液B 1×120μL 检测稀释液B 1×12mLTMB底物1×9mL 终止液1×6mL浓洗涤液(30×) 1×20mL 使用说明书1[需自备的设备及试剂]1、450±10nm 滤光片的酶标仪(建议仪器使用前提前预热)2、单道或多道微量加液器及吸头3、稀释样品的EP 管4、蒸馏水或去离子水5、吸水纸6、盛放洗液的容器[试剂盒的储存及有效期]1、未开封的试剂盒：所有试剂均按试剂瓶标签上所示保存。请注意，收到试剂盒后请尽快将标准品、检测溶液A、检测溶液B 以及96 孔板保存于-20oC。2、使用后的试剂盒：剩余试剂仍需按照试剂瓶标签所示的温度保存，开封后的酶标板要加干燥剂后密封保存于-20oC，避免潮湿。注意：试剂盒内酶标条可拆卸，按实验需求可分多次使用；使用后的剩余试剂盒建议在首次实验后1 个月内使用完毕。产品过期时间以盒子上的标签为准，保质期内所有组分都确保是稳定的。[标本的采集与保存]1、血清：将收集于血清分离管的全血标本在室温放置2 小时或4oC 过夜，然后1000×g 离心20 分钟，取上清即可，或将上清置于-20oC 或-80oC 保存，但应避免反复冻融。2、血浆：用EDTA 或肝素作为抗凝剂采集标本，并将标本在采集后的30 分钟内于2-8oC 1000×g 离心15 分钟，取上清即可检测，或将上清置于-20oC 或-80oC 保存，但应避免反复冻融。3、组织匀浆：1） 取适量组织块，于预冷PBS（0.01mol/L, pH 7.0-7.2）中清洗去除血液，称重后备用（组织块较大需先剪碎后再匀浆）；2） 可同时选用多种匀浆方法达到较好的破碎效果：首先将组织块移入玻璃匀浆器，加入5-10mL 预冷PBS 进行充分研磨，该过程需在冰上进行（有条件实验室可选用机器匀浆）；得到的匀浆液可再利用超声破碎或反复冻融进一步处理（超声破碎过程中注意冰浴降温；反复冻融法可重复2 次）。3） 将制备好的匀浆液于5000×g 离心5 分钟，留取上清即可检测。4、细胞裂解液：1）贴壁细胞需要先用胰酶消化，离心收集细胞（悬浮细胞可直接离心收集）；2）将收集到的细胞用冷PBS 洗3 次；3）物理方法裂解细胞（可先超声破碎细胞，再反复冻融）：i 超声破碎：取适量PBS 重悬细胞，用一定功率的超声波处理细胞悬液，使细胞急剧震荡破裂。ii 反复冻融：将待破碎的细胞在-20oC 以下冰冻，室温融解，反复3 次，使细胞溶胀破碎。4）将标本于2-8oC 1500×g 离心10 分钟，收集上清备用。5、脑脊液：请离心后收集上清，并将标本保存于-20oC，且应避免反复冻融。6、细胞培养上清或其它生物标本：请1000×g 离心20 分钟，取上清即可检测，或将上清置于-20oC 或-80oC 保存，但应避免反复冻融。注意：1、以上标本均需密封保存，4oC 保存应小于1 周，-20oC 不应超过1 个月，-80oC 不应超过2 个月。2、标本溶血会影响最后检测结果，因此溶血标本不宜进行此项检测。3、标本使用前应缓慢均衡至室温，不应加热使之融解。[试剂准备]1、使用前将所有的试剂和标本缓慢均衡至室温(18-25oC)，试剂不能直接在37oC 溶解。2、标准品(冻干品)：每瓶标准品加入标准品稀释液1mL，盖好后室温静置大约10 分钟，同时反复颠倒/搓动以助溶解，其浓度为80ng/mL(贮液)。先将其稀释为10ng/mL(标准曲线最高浓度)后，再准备7 个稀释标准品的EP 管，每个EP 管中加入500μL 的标准品稀释液，如图所示依次倍比稀释成10ng/mL，5ng/mL，2.5ng/mL，1.25ng/mL，0.625ng/mL，0.312ng/mL，0.156ng/mL，标准品稀释液(0ng/mL)直接作为空白孔。为保证实验结果有效性，每次实验请使用新的标准品溶液。Tube 1 2 3 4 5 6 7 8 9ng/mL 80 10 5 2.5 1.25 0.625 0.312 0.156 03、检测溶液A 及检测溶液B：Detection A 及Detection B 在使用前请手甩几下或少时离心处理，以使管壁或瓶盖的液体沉积到管底。临用前分别以检测稀释液A 或B1:100 稀释(如：10μL 检测溶液A/990μL 检测稀释液A)，充分混匀，稀释前根据预先计算好的每次实验所需的总量配制(100μL/孔)，实际配制时应多配制0.1-0.2mL。4、浓洗涤液：用580mL 蒸馏水或去离子水将20mL 浓洗涤液稀释至600mL，进行30 倍稀释。5、底物溶液：请用灭菌的移液器吸头吸取所需体积的TMB 至另一干净容器中使用，容器中剩余的底物应予丢弃，不要倒回TMB 瓶中。注意：1、标准品的稀释不能直接在板中进行。2、标准品请于临用前15 分钟内配制。该标准品只能使用一次。3、标准品、检测溶液A 工作液、检测溶液B 工作液请使用相应的稀释液配制，不能混淆。混匀时要轻轻充分混匀，避免起泡。为保证实验结果的准确请使用微量吸管，并校准微量加液器。请依据所需的量精确配制，尽量不要微量配制(如吸取检测溶液A 时，一次不要小于10μL)，以避免造成浓度误差。4、请勿重复使用已经稀释过的标准品、检测溶液A 工作液和检测溶液B 工作液。5、浓洗涤液中如有结晶析出，请先温育至室温，轻轻混匀，至到结晶完全溶解再进行配制。6、试剂盒中部分试剂为储存液，客户需配置成工作液后使用，在配置过程中如因纯净水质量差或水质污染，以及实验中所用耗材洁净度差，可能造成实验结果不准确，甚至完全错误，请使用双蒸水。[标本处理]1、本公司只对试剂盒本身负责，不对因使用该试剂盒所造成的样本消耗负责，请使用者使用前充分考虑到样本的可能使用量，预留充足的样本。2、实验前应预测标本含量，如果标本浓度过高，应对标本进行稀释，使稀释后的标本符合试剂盒的检测范围，计算时再乘以相应的稀释倍数。标本使用0.01mol/L 的PBS 稀释(PH=7.0-7.2)。3、若所检样本不包含在说明书所列样本之中，建议进行预实验验证其有效性，并注意留存样本。4、使用化学裂解液制备的组织匀浆或细胞提取液可能会由于某些化学物质的引入导致ELISA 实验结果偏差。5、若样本为细胞培养上清，因该类样本干扰因素较多，如：细胞状态、细胞数量、采样时间等，所以可能存在检测不出的情况。6、某些天然蛋白或重组蛋白，包括原核及真核重组蛋白，可能因为与本产品所使用的检测抗体及捕获抗体不匹配，而不被检测出。7、建议使用新鲜样本，保存时间过长可能会存在蛋白降解或变性导致实验结果偏差。[操作步骤]1、加样：分别设标准孔、待测样品孔、空白孔。设标准孔7 孔，依次加入100μL 不同浓度的标准品(见试剂准备2)。空白孔加100μL(见试剂准备第二步最后一管)，余孔加待测样品100μL，酶标板加上覆膜，37oC 温育2 小时。2、弃去液体，甩干，不用洗涤。3、每孔加检测溶液A 工作液100μL(临用前配制)，酶标板加上覆膜，37oC 温育1 小时。4、弃去孔内液体，每孔用350μL 的洗涤液洗涤，浸泡1-2 分钟，吸去(不可触及板壁)或甩掉酶标板内的液体，在实验台上铺垫几层吸水纸，酶标板朝下用力拍几次(也可轻拍将孔内液体拍干)，重复洗板3 次。最后一次洗涤后，要把孔内的洗涤液完全甩干。自动洗板机亦可。5、每孔加检测溶液B 工作液(临用前配制)100μL，加上覆膜，37oC 温育30 分钟。6、弃去孔内液体，甩干，洗板5 次，方法同步骤4。7、每孔加底物溶液90μL，酶标板加上覆膜，37oC 避光显色(反应时间控制在15-25 分钟，不要超过30 分钟。当标准孔的前3-4 孔有明显的梯度蓝色，后3-4 孔梯度不明显时，即可终止)。8、每孔加终止溶液50μL，终止反应，此时蓝色立转黄色。终止液的加入顺序应尽量与底物溶液的加入顺序相同。如出现颜色不匀一，请轻轻晃动酶标板以使溶液混合均匀。9、在确保酶标板底无水滴及孔内无气泡后，立即用酶标仪在450nm 波长测量各孔的光密度(O.D.值)。注意：1、试剂准备：准备一次实验所需要的酶标条，其它的可从微孔板上拆下，密封，按照说明书要求保存，以备下次使用。2、加样：实验操作中请使用一次性的吸头，避免交叉污染。加样时注意不要有气泡，将样品加于酶标板底部，尽量不触及孔壁，轻轻晃动混匀。加样或加试剂时，第一个孔与最后一个孔加样之间的时间间隔如果太大，将会导致不同的“预温育”时间，从而明显地影响到测量值的准确性及重复性。因此，一次加样时间(包括标准品及所有样品)最好控制在10 分钟内。推荐设置复孔进行实验。3、温育：为防止样品蒸发，实验时请将加上盖或覆膜的酶标板置于湿盒内，以避免液体蒸发，洗板后应尽快进行下步操作，任何时侯都应避免酶标板处于干燥状态，同时应严格遵守给定的温育时间和温度。4、洗涤：充分的洗涤非常重要，在每次洗涤过程中，都要将洗涤液完全甩干。洗涤过程中反应孔中残留的洗涤液应在滤纸上拍干，勿将滤纸直接放入反应孔中吸水，同时要消除板底残留的液体和手指印，避免影响最后的酶标仪读数。如果有自动洗板机，应在熟练使用后再用到正式实验过程中。5、反应时间的控制：加入底物后请定时观察反应孔的颜色变化(比如，每隔10 分钟观察一次)，如颜色较深，请提前加入终止液终止反应，避免反应过强从而影响酶标仪光密度读数。6、底物：底物请避光保存，在储存和温育时避免强光直接照射。7、如果实验室内湿度低于60%，推荐使用加湿器提高湿度水平。[实验原理]将GDNF 抗体包被于96 孔微孔板中，制成固相载体，向微孔中分别加入标准品或标本，其中的GDNF 与连接于固相载体上的抗体结合，然后加入生物素化的GDNF 抗体，将未结合的生物素化抗体洗净后，加入HRP 标记的亲和素，再次彻底洗涤后加入TMB 底物显色。TMB 在过氧化物酶的催化下转化成蓝色，并在酸的作用下转化成最终的黄色。颜色的深浅和样品中的GDNF 呈正相关。用酶标仪在450nm 波长下测定吸光度(O.D.值)，计算样品浓度。[计算]各标准品及样本O.D.值扣除空白孔O.D.值后作图(七点图)，如设置复孔，则应取其平均值计算。以标准品的浓度为纵坐标(或对数坐标)，O.D.值为横坐标(或对数坐标），绘出标准曲线(最佳方程式应依回归方程计算的R2值来定，以R2 值越趋近于1 为好)。推荐使用专业制作曲线软件进行分析，如curve expert 1.30，根据样品O.D.值，由标准曲线查出相应的浓度，乘以稀释倍数；或用标准物的浓度与O.D.值计算出标准曲线的回归方程式，将样品的O.D.值代入方程式，计算出样品浓度，再乘以稀释倍数，即为样品的实际浓度。[典型数据]为了便于计算，尽管浓度为自变量而O.D.值为因变量，我们绘图时仍采用标准品的O.D.值作为横坐标(X 轴)，标准品的浓度为纵坐标(Y 轴)。同时为了试验结果的直观性，图中提供的是原始数据而非对数值。推荐使用对数值建立标准曲线图。由于实验操作条件的不同（如操作者、移液技术、洗板技术和温度条件等），标准曲线的O.D.值会有所差异。所提供的标准曲线仅供参考，实验者需要根据自已的实验建立标准曲线。人胶质细胞系来源神经营养因子(GDNF)检测试剂盒标准曲线[检测范围]0.156ng/mL-10ng/mL[最低检测限]0.062ng/mL此值为20 个空白样品(即标准品稀释液)测定的平均值加二倍标准差所对应的浓度。[特异性]本试剂盒用于检测GDNF，经检测与其它相似物质无明显交叉反应。由于受到技术及样本来源的限制，不可能完成对所有相关或相似物质交叉反应检测，因此本试剂盒有可能与未经检测的其它物质有交叉反应。[回收率]分别于定值血清及血浆样本中加入一定量的GDNF（加标样品），重复测定并计算其均值，回收率为测定值与理论值的比率。样本回收率范围(%) 平均回收率(%)血清(n=5) 86-98 92EDTA 血浆(n=5) 88-101 95肝素血浆(n=5) 91-104 97[线性]在定值血清及血浆样本内加入适量的GDNF，并倍比稀释成1:2，1:4，1:8，1:16 的待测样本，线性范围即为稀释后样本中GDNF 含量的测定值与理论值的比率。样本1：2 1：4 1：8 1：16血清(n=5) 92-104% 90-99% 88-104% 85-95%EDTA 血浆(n=5) 84-96% 80-94% 92-99% 90-102%肝素血浆(n=5) 79-94% 88-101% 95-106% 83-97%[精密度]精密度用样品测定值的变异系数CV 表示。CV(%) = SD/mean×100批内差：取同批次试剂盒对低、中、高值定值样本进行定量检测,每份样本连续测定20 次，分别计算不同浓度样本的平均值及SD 值。批间差：选取3 个不同批次的试剂盒分别对低、中、高值定值样本进行定量测定，每个样本使用同一试剂盒重复测定8 次，分别计算不同浓度样本的平均值及SD 值。批内差： CV批间差： CV[稳定性]经测定，试剂盒在有效期内按推荐温度保存，其活性降低率小于5%。为减小外部因素对试剂盒破坏前后检测值的影响，实验室的环境条件需尽量保持一致，尤其是实验室内温度、湿度及温育条件。其次由同一实验员来进行操作可减少人为误差。[实验流程]1、实验前标准品、试剂及样本的准备；2、加样（标准品及样本）100μL，37oC孵育2小时；3、吸弃，加检测溶液A100μL，37oC孵育1小时；4、洗板3次；5、加检测溶液B100μL，37oC孵育30分钟；6、洗板5次；7、加TMB底物90μL，37oC孵育15－25分钟；8、加终止液50μL，立即450nm读数。[说明]1、由于现有条件及科学技术水平尚不能对所有供货商提供的所有原料进行全面的鉴定与分析，本产品可能存在一定的质量技术风险。2、最终的实验结果与试剂的有效性、实验者的相关操作以及当时的实验环境密切相关，请务必准备充足的标本备份。3、不同批次的同一产品可能会有少许差别，如：检测限、灵敏度以及显色时间等，请依据试剂盒内说明书进行实验操作，网站电子版说明书仅作参考。4、只有全部使用本试剂盒配套试剂才能保证检测效果，不能混用其他制造商的产品。只有严格遵守本试剂盒的实验说明才会得到最佳的检测结果。5、在储存及温育过程中避免将试剂暴露在强光中。所有试剂瓶盖须盖紧以防止蒸发和微生物的污染，因为蛋白水解酶的干扰将导致出现错误的结果。6、刚开启的酶联板孔中可能会有少许水样物质，此为正常现象，不会对实验结果造成任何影响。请勿提前将酶标板从包装袋里拿出。7、由于操作者不熟练、操作失误或读数仪程序选用错误等有可能会导致错误结果的产生。请使用者使用该产品前仔细阅读说明书，调试好酶标仪，请使用配备有450±10nm 滤光片的酶标仪，且该酶标仪测量范围在0.001-3.000 O.D.或以上。8、同一使用者在使用同一产品时，如不同时间订购，也可能会因不同批次的少量差异产生不同结果，因此建议使用者在每次使用前均进行预实验。9、试剂盒在出厂前均经过严格检测，但由于运输条件及各实验室条件差异，可能会造成实验结果与出厂结果不一致或不同批次试剂盒批间差大的情况，对于这种情况会酌情处理。10、本试剂盒未与其他厂家同类试剂盒或不同方法检测同一目的蛋白的产品做对比，平行检测可能会存在检测结果不一致的情况。11、本操作说明同样适用于48T 试剂盒，但48T 试剂盒所有试剂减半。[警告]本试剂盒中使用了稀硫酸作为终止液，其具有轻微腐蚀性，使用时应避免接触衣物或眼、手等皮肤暴露部位。[问题解答]问题可能原因解决方案标准曲线差标准品准备不正确进行正确的标准品梯度稀释吸取及洗涤不充分充分的吸取及洗涤移液不精确检查和校正移液器精密度低洗涤不充分按说明书要求充分洗涤和浸泡混匀不充分和吸取试剂不足充分混匀和吸取试剂重复利用吸头、容器和覆膜使用加样器要更换新的吸头、使用新的容器和覆膜加样不精确检查和校正移液器O.D 值低每孔加的试剂量不精确校正移液器，精确加入试剂温育时间不正确保证充足的温育时间温育温度不正确试剂要平衡至室温并保证准确的温育温度酶标记物或底物失效通过混合酶标记物和底物，颜色应迅速显现来检查没有加入终止液按照说明书实验操作步骤加入终止液超出读数时间读数在说明书推荐的读数时间内读数样本值不正确的样本储存方式正确储存样本，使用新鲜样本进行实验不正确的样本收集和处理方法采取正确的样本收集和处理方法待测物质在样本中含量低使用新鲜样本，重复实验 

得益于全球首个对抗疟疾和寄生虫病的疫苗日前表现出的良好效果，一种在撒哈拉沙漠以南非洲每天导致约1300名儿童死亡的疾病或许将很快得到遏制。该疫苗的开发商希望，在获得这些结果后，它将在今年年末得到官方的使用许可。不过，上述疫苗有可能在明年或更晚的时候在单个非洲国家消除监管障碍。总部位于美国华盛顿的适宜卫生科技组织疟疾疫苗项目和英国制药公司葛兰素史克（GSK）共同开发了RTS，S疫苗。它已在疟疾盛行的7个非洲国家的15459名儿童身上进行了试验。接受测试的人根据年龄被分为6～12周的婴儿，以及5～17个月的儿童，以便观察该疫苗在哪个年龄段表现得最好。所有儿童均在两个月内接受了3次注射，一些还在18个月后接受了加强剂量的注射。结果显示，当年龄较大儿童还接受了额外的加强剂量注射时，RTS，S疫苗的表现最好，4年中将疟疾的病例减少了36%。如果他们没有接受加强剂量，该数字会降到28%。此前，14个月时的中期结果表明，发生在这些儿童中的疟疾病例减半，因此最新数据证实保护效应随着时间减退。在婴儿中，加强剂量接受者的病例数减少了26%，非接受者群体则减少了18%。加强剂量还在年龄较大儿童而非婴儿中提供了针对严重疟疾的较好保护。随着结果出来，全球监管机构正在准备审批事宜。欧洲药品管理局正在评估GSK的申请，并且有望在今年9月作出决定。